## Jeffrey Lipman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5251153/publications.pdf

Version: 2024-02-01

585	33,266	87 h-index	158
papers	citations		g-index
605	605	605	20887
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Microsampling to support pharmacokinetic clinical studies in pediatrics. Pediatric Research, 2022, 91, 1557-1561.	1.1	6
2	Antibiotic dosing in sustained low-efficiency daily dialysis (SLEDD): Basic concepts and dosing strategies. Journal of Critical Care, 2022, 67, 104-107.	1.0	1
3	Evaluation of low-volume plasma sampling for the analysis of meropenem in clinical samples. Analytical and Bioanalytical Chemistry, 2022, 414, 2155-2162.	1.9	7
4	Effect of Different Piperacillin-Tazobactam Dosage Regimens on Synergy of the Combination with Tobramycin against Pseudomonas aeruginosa for the Pharmacokinetics of Critically Ill Patients in a Dynamic Infection Model. Antibiotics, 2022, 11, 101.	1.5	4
5	Pharmacodynamics of ceftriaxone for the treatment of methicillinâ€susceptible Staphylococcus aureus: is it a viable treatment option?. International Journal of Antimicrobial Agents, 2022, 59, 106537.	1.1	10
6	Innovation in microsampling for therapeutic drug monitoring of gentamicin in neonates: a proof-of-concept study. International Journal of Antimicrobial Agents, 2022, 59, 106513.	1.1	1
7	Population Pharmacokinetics of Intraperitoneal Gentamicin and the Impact of Varying Dwell Times on Pharmacodynamic Target Attainment in Patients with Acute Peritonitis Undergoing Peritoneal Dialysis. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0167921.	1.4	4
8	Population Pharmacokinetic Model of Piperacillin in Critically III Patients and Describing Interethnic Variation Using External Validation. Antibiotics, 2022, 11, 434.	1.5	1
9	Use of Antimicrobials for Bloodstream Infections in the Intensive Care Unit, a Clinically Oriented Review. Antibiotics, 2022, $11,362$ .	1.5	13
10	A Narrative Review on the Approach to Antimicrobial Use in Ventilated Patients with Multidrug Resistant Organisms in Respiratory Samplesâ€"To Treat or Not to Treat? That Is the Question. Antibiotics, 2022, 11, 452.	1.5	2
11	An international survey of adherence to Surviving Sepsis Campaign Guidelines 2016 regarding fluid resuscitation and vasopressors in the initial management of septic shock. Journal of Critical Care, 2022, 68, 144-154.	1.0	15
12	Caspofungin Population Pharmacokinetic Analysis in Plasma and Peritoneal Fluid in Septic Patients with Intra-Abdominal Infections: A Prospective Cohort Study. Clinical Pharmacokinetics, 2022, 61, 673-686.	1.6	3
13	Precision dosing software to optimize antimicrobial dosing: a systematic search and follow-up survey of available programs. Clinical Microbiology and Infection, 2022, 28, 1211-1224.	2.8	13
14	Epidemiology and age-related mortality in critically ill patients with intra-abdominal infection or sepsis: an international cohort study. International Journal of Antimicrobial Agents, 2022, 60, 106591.	1.1	14
15	Multicenter Population Pharmacokinetic Study of Unbound Ceftriaxone in Critically Ill Patients. Antimicrobial Agents and Chemotherapy, 2022, 66, e0218921.	1.4	8
16	Optimal dosing of cefotaxime and desacetylcefotaxime for critically ill paediatric patients. Can we use microsampling?. Journal of Antimicrobial Chemotherapy, 2022, 77, 2227-2237.	1.3	1
17	Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Meropenem in Neurocritical Care Patients: a Prospective Two-Center Study. Antimicrobial Agents and Chemotherapy, 2022, 66, .	1.4	5
18	The Effect of Renal Replacement Therapy and Antibiotic Dose on Antibiotic Concentrations in Critically III Patients: Data From the Multinational Sampling Antibiotics in Renal Replacement Therapy Study. Clinical Infectious Diseases, 2021, 72, 1369-1378.	2.9	85

#	Article	IF	CITATIONS
19	Ceftriaxone dosing in patients admitted from the emergency department with sepsis. European Journal of Clinical Pharmacology, 2021, 77, 207-214.	0.8	3
20	Population Pharmacokinetics of Levetiracetam in Patients with Traumatic Brain Injury and Subarachnoid Hemorrhage Exhibiting Augmented Renal Clearance. Clinical Pharmacokinetics, 2021, 60, 655-664.	1.6	16
21	A narrative review on antimicrobial therapy in septic shock: updates and controversies. Current Opinion in Anaesthesiology, 2021, 34, 92-98.	0.9	2
22	Ventilation practices in burn patientsâ€"an international prospective observational cohort study. Burns and Trauma, 2021, 9, tkab034.	2.3	2
23	A Loading Micafungin Dose in Critically Ill Patients Undergoing Continuous Venovenous Hemofiltration or Continuous Venovenous Hemodiafiltration: A Population Pharmacokinetic Analysis. Therapeutic Drug Monitoring, 2021, 43, 747-755.	1.0	3
24	Protocol for an international, multicentre, prospective, observational study of nosocomial pneumonia in intensive care units: the PneumolNSPIRE study. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2021, 23, 59-66.	0.0	0
25	Reâ€expansion pulmonary oedema with Takotsubo cardiomyopathy: a rare complication of giant hepatic cyst drainage. ANZ Journal of Surgery, 2021, 91, 2524-2527.	0.3	1
26	Genomic surveillance, characterization and intervention of a polymicrobial multidrug-resistant outbreak in critical care. Microbial Genomics, $2021, 7, \ldots$	1.0	22
27	Evaluation of Meropenemâ€Ciprofloxacin Combination Dosage Regimens for the Pharmacokinetics of Critically III Patients With Augmented Renal Clearance. Clinical Pharmacology and Therapeutics, 2021, 104-1115.	2.3	16
28	An international survey on aminoglycoside practices in critically ill patients: the AMINO III study. Annals of Intensive Care, 2021, 11, 49.	2.2	15
29	The Australian response to the COVID-19 pandemic: A co-ordinated and effective strategy. Anaesthesia, Critical Care & Description (2021), 40, 100859.	0.6	14
30	Impact of the Epithelial Lining Fluid Milieu on Amikacin Pharmacodynamics Against Pseudomonas aeruginosa. Drugs in R and D, 2021, 21, 203-215.	1.1	2
31	Lorazepam challenge test for catatonia. EMA - Emergency Medicine Australasia, 2021, 33, 763-764.	0.5	2
32	Development and validation of a UHPLC-MS/MS method to measure cefotaxime and metabolite desacetylcefotaxime in blood plasma: a pilot study suitable for capillary microsampling in critically ill children. Analytical and Bioanalytical Chemistry, 2021, 413, 4483-4491.	1.9	2
33	Influence of the Obesity Phenotype on the Adequacy of Antibiotic Prophylaxis with Cefoxitin for Obese Patients Undergoing Bariatric Surgery: Lessons Learnt and Future Considerations. European Journal of Drug Metabolism and Pharmacokinetics, 2021, 46, 479-485.	0.6	3
34	A Multicenter Observational Study Evaluating Outcomes Associated With Antibiotic Combination Versus Monotherapy in Patients With Septic Shock. , 2021, 3, e0383.		0
35	Antimicrobial Lessons From a Large Observational Cohort on Intra-abdominal Infections in Intensive Care Units. Drugs, 2021, 81, 1065-1078.	4.9	13
36	Prospective Cohort Study of Micafungin Population Pharmacokinetic Analysis in Plasma and Peritoneal Fluid in Septic Patients with Intra-abdominal Infections. Antimicrobial Agents and Chemotherapy, 2021, 65, e0230720.	1.4	4

#	Article	IF	CITATIONS
37	Pharmacodynamics of once-versus twice-daily dosing of nebulized amikacin in an in vitro Hollow-Fiber Infection Model against 3 clinical isolates of Pseudomonas aeruginosa. Diagnostic Microbiology and Infectious Disease, 2021, 100, 115329.	0.8	2
38	Optimising Treatment Outcomes for Children and Adults Through Rapid Genome Sequencing of Sepsis Pathogens. A Study Protocol for a Prospective, Multi-Centre Trial (DIRECT). Frontiers in Cellular and Infection Microbiology, 2021, 11, 667680.	1.8	10
39	Initial antimicrobial management of sepsis. Critical Care, 2021, 25, 307.	2.5	58
40	Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC β-Lactamase–Producing ⟨i⟩Enterobacter⟨ i⟩ spp, ⟨i⟩Citrobacter freundii⟨ i⟩, ⟨i⟩Morganella morganii⟨ i⟩, ⟨i⟩Providencia⟨ i⟩ spp, or ⟨i⟩Serratia marcescens⟨ i⟩: A Pilot Multicenter Randomized Controlled Trial (MERINO-2). Open Forum Infectious Diseases, 2021, 8, ofab387.	0.4	42
41	Pharmacokinetics of fluconazole and ganciclovir as combination antimicrobial chemotherapy on ECMO: a case report. International Journal of Antimicrobial Agents, 2021, 58, 106431.	1.1	5
42	Statistical analysis plan for the BLING III study: a phase 3 multicentre randomised controlled trial of continuous versus intermittent $\hat{l}^2$ -lactam antibiotic infusion in critically ill patients with sepsis. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2021, 23, 273-284.	0.0	O
43	Global personalization of antibiotic therapy in critically ill patients. Expert Review of Precision Medicine and Drug Development, 2021, 6, 87-93.	0.4	4
44	Ventriculitis: Infection or Inflammation. Antibiotics, 2021, 10, 1246.	1.5	5
45	A personalised approach to antibiotic pharmacokinetics and pharmacodynamics in critically ill patients. Anaesthesia, Critical Care & Delical Medicine, 2021, 40, 100970.	0.6	21
46	A validated LC-MS/MS method for the simultaneous quantification of the novel combination antibiotic, ceftolozane–tazobactam, in plasma (total and unbound), CSF, urine and renal replacement therapy effluent: application to pilot pharmacokinetic studies. Clinical Chemistry and Laboratory Medicine, 2021, 59, 921-933.	1.4	4
47	Micafungin Population PK Analysis in Healthy and Septic Pigs: Can the Septic Porcine Model Predict the Micafungin PK in Septic Patients?. Pharmaceutical Research, 2021, 38, 1863-1871.	1.7	O
48	Is Dosing of Ethambutol as Part of a Fixed-Dose Combination Product Optimal for Mechanically Ventilated ICU Patients with Tuberculosis? A Population Pharmacokinetic Study. Antibiotics, 2021, 10, 1559.	1.5	3
49	$\hat{l}^2$ -Lactam pharmacodynamics in Gram-negative bloodstream infections in the critically ill. Journal of Antimicrobial Chemotherapy, 2020, 75, 429-433.	1.3	35
50	When not to start antibiotics: avoiding antibiotic overuse in the intensive care unit. Clinical Microbiology and Infection, 2020, 26, 35-40.	2.8	39
51	$\hat{l}^2$ -lactam antibiotic versus combined $\hat{l}^2$ -lactam antibiotics and single daily dosing regimens of aminoglycosides for treating serious infections: A meta-analysis. International Journal of Antimicrobial Agents, 2020, 55, 105839.	1.1	21
52	Development and validation of LC-MS/MS methods to measure tobramycin and lincomycin in plasma, microdialysis fluid and urine: application to a pilot pharmacokinetic research study. Clinical Chemistry and Laboratory Medicine, 2020, 58, 274-284.	1.4	8
53	Cerebrospinal Fluid Penetration of Ceftolozane-Tazobactam in Critically Ill Patients with an Indwelling External Ventricular Drain. Antimicrobial Agents and Chemotherapy, 2020, 65, .	1.4	15
54	A Systematic Review of Studies Reporting Antibiotic Pharmacokinetic Data in the Cerebrospinal Fluid of Critically III Patients with Uninflamed Meninges. Antimicrobial Agents and Chemotherapy, 2020, 65, .	1.4	9

#	Article	IF	CITATIONS
55	Pharmacodynamic Evaluation of Plasma and Epithelial Lining Fluid Exposures of Amikacin against Pseudomonas aeruginosa in a Dynamic <i>In Vitro</i> Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	7
56	Vancomycin Serum Concentration after 48 h of Administration: A 3-Years Survey in an Intensive Care Unit. Antibiotics, 2020, 9, 793.	1.5	6
57	Infection, Sepsis and the Inflammatory Response: Mechanisms and Therapy. Frontiers in Medicine, 2020, 7, 588863.	1.2	14
58	Prolonged Versus Intermittent Infusion of $\hat{I}^2$ -Lactam Antibiotics: A Systematic Review and Meta-Regression of Bacterial Killing in Preclinical Infection Models. Clinical Pharmacokinetics, 2020, 59, 1237-1250.	1.6	18
59	Ticarcillin and piperacillin adsorption on to polyethersulfone haemodiafilter membranes in an ex-vivo circuit. International Journal of Antimicrobial Agents, 2020, 56, 106058.	1.1	4
60	Pulmonary infections complicating ARDS. Intensive Care Medicine, 2020, 46, 2168-2183.	3.9	69
61	An Integrated Dialysis Pharmacometric (IDP) Model to Evaluate the Pharmacokinetics in Patients Undergoing Renal Replacement Therapy. Pharmaceutical Research, 2020, 37, 96.	1.7	10
62	Pharmacokinetics of Sulfamethoxazole and Trimethoprim During Venovenous Extracorporeal Membrane Oxygenation: A Case Report. Pharmacotherapy, 2020, 40, 713-717.	1.2	1
63	Comparative Plasma Pharmacokinetics of Ceftriaxone and Ertapenem in Normoalbuminemia, Hypoalbuminemia, and Albumin Replacement in a Sheep Model. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	4
64	Antimicrobial de-escalation in the critically ill patient and assessment of clinical cure: the DIANA study. Intensive Care Medicine, 2020, 46, 1404-1417.	3.9	54
65	Pharmacokinetic and pharmacodynamic considerations in antimicrobial therapy for sepsis. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 415-430.	1.5	14
66	Development of Population and Bayesian Models for Applied Use in Patients Receiving Cefepime. Clinical Pharmacokinetics, 2020, 59, 1027-1036.	1.6	11
67	Conventional Pig as Animal Model for Human Renal Drug Excretion Processes: Unravelling the Porcine Renal Function by Use of a Cocktail of Exogenous Markers. Frontiers in Pharmacology, 2020, 11, 883.	1.6	14
68	Pharmacodynamic evaluation of intermittent versus extended and continuous infusions of piperacillin/tazobactam in a hollow-fibre infection model against Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy, 2020, 75, 2633-2640.	1.3	12
69	Prophylactic Cefazolin Dosing in Women With Body Mass Index >35 kg·mâ^'2 Undergoing Cesarean Delivery: A Pharmacokinetic Study of Plasma and Interstitial Fluid. Anesthesia and Analgesia, 2020, 131, 199-207.	1.1	14
70	Antimicrobial de-escalation is part of appropriate antibiotic usage in ICU. Intensive Care Medicine, 2020, 46, 1039-1042.	3.9	4
71	Integrating multiple genomic technologies to investigate an outbreak of carbapenemase-producing Enterobacter hormaechei. Nature Communications, 2020, $11$ , $466$ .	5.8	34
72	Antimicrobial-associated harm in critical care: a narrative review. Intensive Care Medicine, 2020, 46, 225-235.	3.9	86

#	Article	IF	Citations
73	Emerging Treatment Options for Infections by Multidrug-Resistant Gram-Positive Microorganisms. Microorganisms, 2020, 8, 191.	1.6	29
74	New guidelines for the management of severe thermal burns in the acute phase in adults and children: Is it time for a global surviving burn injury campaign (SBIC)?. Anaesthesia, Critical Care & Description (SBIC)?. Anaesthesia, Critical Care & Description (SBIC) (SBIC	0.6	0
75	Pharmacokinetic/pharmacodynamic adequacy of polymyxin B against extensively drug-resistant Gram-negative bacteria in critically ill, general ward and cystic fibrosis patient populations. International Journal of Antimicrobial Agents, 2020, 55, 105943.	1.1	16
76	On-Site Therapeutic Drug Monitoring. Trends in Biotechnology, 2020, 38, 1262-1277.	4.9	128
77	There is no fire without smoke! Pathophysiology and treatment of inhalational injury in burns: A narrative review. Anaesthesia and Intensive Care, 2020, 48, 114-122.	0.2	5
78	International facilitators and barriers to family engagement in the ICU: Results of a qualitative analysis. Journal of Critical Care, 2020, 58, 72-77.	1.0	27
79	Optimization of flucloxacillin dosing regimens in critically ill patients using population pharmacokinetic modelling of total and unbound concentrations. Journal of Antimicrobial Chemotherapy, 2020, 75, 2641-2649.	1.3	18
80	Early Sequential Microcirculation Assessment in Shocked Patients as a Predictor of Outcome. Shock, 2020, Publish Ahead of Print, 581-586.	1.0	10
81	Ventilator-Associated Tracheobronchitis: To Treat or Not to Treat?. Antibiotics, 2020, 9, 51.	1.5	13
82	Epidemiology and Microbiology of Severe Communityâ€Acquired Pneumonia in Central Australia: A Retrospective Study. Internal Medicine Journal, 2020, , .	0.5	3
83	A Robust Statistical Approach to Analyse Population Pharmacokinetic Data in Critically Ill Patients Receiving Renal Replacement Therapy. Clinical Pharmacokinetics, 2019, 58, 263-270.	1.6	0
84	Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms. Microorganisms, 2019, 7, 270.	1.6	63
85	What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review. Clinical Pharmacokinetics, 2019, 58, 1407-1443.	1.6	106
86	A Multicenter Trial of Vena Cava Filters in Severely Injured Patients. New England Journal of Medicine, 2019, 381, 328-337.	13.9	117
87	Population pharmacokinetics of ticarcillin in critically ill patients receiving extended daily diafiltration. International Journal of Antimicrobial Agents, 2019, 54, 351-355.	1.1	2
88	Vena Cava filters in severely-injured patients: One size does not fit all. Anaesthesia, Critical Care & Pain Medicine, 2019, 38, 305-307.	0.6	8
89	Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically Ill Patients without Renal Dysfunction. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	35
90	Epidemiology of intra-abdominal infection and sepsis in critically ill patients: "AbSeS― a multinational observational cohort study and ESICM Trials Group Project. Intensive Care Medicine, 2019, 45, 1703-1717.	3.9	103

#	Article	IF	CITATIONS
91	Pharmacokinetics of Total and Unbound Cefazolin during Veno-Arterial Extracorporeal Membrane Oxygenation: A Case Report. Chemotherapy, 2019, 64, 115-118.	0.8	4
92	Lefamulin. Comment on: "Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms. Microorganisms, 2019, 7, 270― Microorganisms, 2019, 7, 386.	1.6	14
93	Saturable elimination of piperacillin in critically ill patients: implications for continuous infusion. International Journal of Antimicrobial Agents, 2019, 54, 741-749.	1.1	14
94	The relationship between ventilator-associated pneumonia and chronic obstructive pulmonary disease: what is the current evidence?. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 637-647.	1.3	12
95	Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patients. Critical Care, 2019, 23, 205.	2.5	22
96	Does intermittent pneumatic compression PREVENT deep vein thrombosis in the ICU?. Anaesthesia, Critical Care & Does in Medicine, 2019, 38, 303-304.	0.6	5
97	Antibiotic exposure at the site of infection: principles and assessment of tissue penetration. Expert Review of Clinical Pharmacology, 2019, 12, 623-634.	1.3	36
98	Evaluation of pharmacokinetic/pharmacodynamic and clinical outcomes with 6-hourly empiric piperacillin-tazobactam dosing in hematological malignancy patients with febrile neutropenia. Journal of Infection and Chemotherapy, 2019, 25, 503-508.	0.8	8
99	Analysis of capillary microsamples obtained from a skin-prick to measure vancomycin concentrations as a valid alternative to conventional sampling: A bridging study. Journal of Pharmaceutical and Biomedical Analysis, 2019, 169, 288-292.	1.4	12
100	Early target attainment of continuous infusion piperacillin/tazobactam and meropenem in critically ill patients: A prospective observational study. Journal of Critical Care, 2019, 52, 75-79.	1.0	25
101	In-vitro adsorption and sieving coefficient of ticarcillin-clavulanate during continuous haemofiltration. International Journal of Antimicrobial Agents, 2019, 54, 261-264.	1.1	7
102	Challenges in the management of septic shock: a narrative review. Intensive Care Medicine, 2019, 45, 420-433.	3.9	52
103	Defining optimal dosing of ciprofloxacin in patients with septic shock. Journal of Antimicrobial Chemotherapy, 2019, 74, 1662-1669.	1.3	18
104	1573. Population Pharmacokinetic Analyses for Cefepime in Adult and Pediatric Patients. Open Forum Infectious Diseases, 2019, 6, S574-S575.	0.4	0
105	Amoxicillin-Clavulanate Dosing in the Intensive Care Unit: The Additive Effect of Renal Replacement Therapy in a Patient with Normal Kidney Function. Chemotherapy, 2019, 64, 173-176.	0.8	4
106	Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically III Patients. Antimicrobial Agents and Chemotherapy, 2019, 64, .	1.4	21
107	A validated LC-MSMS method for the simultaneous quantification of meropenem and vaborbactam in human plasma and renal replacement therapy effluent and its application to a pharmacokinetic study. Analytical and Bioanalytical Chemistry, 2019, 411, 7831-7840.	1.9	11
108	A Population Pharmacokinetic Model-Guided Evaluation of Ceftolozane-Tazobactam Dosing in Critically III Patients Undergoing Continuous Venovenous Hemodiafiltration. Antimicrobial Agents and Chemotherapy, 2019, 64, .	1.4	21

#	Article	IF	CITATIONS
109	Pharmacokinetics of Enteric-Coated Mycophenolate Sodium in Lupus Nephritis (POEMSLUN). Therapeutic Drug Monitoring, 2019, 41, 703-713.	1.0	7
110	Antimicrobial Resistance: We Must Pursue a Collaborative, Global Approach and Use a "One Health― Approach. Antibiotics, 2019, 8, 237.	1.5	2
111	Population pharmacokinetics and evaluation of the predictive performance of pharmacokinetic models in critically ill patients receiving continuous infusion meropenem: a comparison of eight pharmacokinetic models. Journal of Antimicrobial Chemotherapy, 2019, 74, 432-441.	1.3	43
112	Intrapulmonary pharmacokinetics of antibiotics used to treat nosocomial pneumonia caused by Gram-negative bacilli: A systematic review. International Journal of Antimicrobial Agents, 2019, 53, 234-245.	1.1	45
113	Infections by multidrug-resistant Gram-negative Bacteria: What's new in our arsenal and what's in the pipeline?. International Journal of Antimicrobial Agents, 2019, 53, 211-224.	1.1	68
114	Plasma and interstitial fluid population pharmacokinetics of vancomycin in critically ill patients with sepsis. International Journal of Antimicrobial Agents, 2019, 53, 137-142.	1.1	14
115	A protocol for a phase 3 multicentre randomised controlled trial of continuous versus intermittent $\hat{l}^2$ -lactam antibiotic infusion in critically ill patients with sepsis: BLING III. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2019, 21, 63-68.	0.0	10
116	Survey of critical care practice in Australian and New Zealand burn referral centres. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2019, 21, 303-304.	0.0	1
117	Characteristics, treatment and outcomes for all emergency department patients fulfilling criteria for septic shock: a prospective observational study. European Journal of Emergency Medicine, 2018, 25, 97-104.	0.5	12
118	Pharmacokinetics of piperacillin in critically ill patients with acute kidney injury receiving sustained low-efficiency diafiltration. Journal of Antimicrobial Chemotherapy, 2018, 73, 1647-1650.	1.3	16
119	Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	21
120	Utility of communityâ€acquired pneumonia severity scores in guiding disposition from the emergency department: Intensive care or shortâ€stay unit?. EMA - Emergency Medicine Australasia, 2018, 30, 538-546.	0.5	8
121	Pharmacokinetics of Intravenous Posaconazole in Critically III Patients. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	17
122	Is augmented renal clearance the Holy Grail of antibiotic therapy failure in ventilator-acquired pneumonia?. Anaesthesia, Critical Care & Dain Medicine, 2018, 37, 5-6.	0.6	1
123	Re: †ls a randomized trial of a short course of aminoglycoside added to β-lactam antibiotics for empirical treatment in critically ill patients with sepsis justified?' Pharmacokinetic/pharmacodynamic considerations. Clinical Microbiology and Infection, 2018, 24, 666-667.	2.8	1
124	Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM/ESCMID/WAAAR round table on multi-drug resistance. Intensive Care Medicine, 2018, 44, 189-196.	3.9	101
125	Differences in suppression of regrowth and resistance despite similar initial bacterial killing for meropenem and piperacillin/tazobactam against Pseudomonas aeruginosa and Escherichia coli. Diagnostic Microbiology and Infectious Disease, 2018, 91, 69-76.	0.8	4
126	Individualising Therapy to Minimize Bacterial Multidrug Resistance. Drugs, 2018, 78, 621-641.	4.9	48

#	Article	IF	Citations
127	Clinical application of microsampling versus conventional sampling techniques in the quantitative bioanalysis of antibiotics: a systematic review. Bioanalysis, 2018, 10, 407-423.	0.6	25
128	Population pharmacokinetics of vancomycin in critically ill patients receiving prolonged intermittent renal replacement therapy. International Journal of Antimicrobial Agents, 2018, 52, 151-157.	1.1	25
129	Maximally effective dosing regimens of meropenem in patients with septic shock. Journal of Antimicrobial Chemotherapy, 2018, 73, 191-198.	1.3	40
130	A UHPLC–MS/MS method for the simultaneous determination of piperacillin and tazobactam in plasma (total and unbound), urine and renal replacement therapy effluent. Journal of Pharmaceutical and Biomedical Analysis, 2018, 148, 324-333.	1.4	23
131	The effects of major burn related pathophysiological changes on the pharmacokinetics and pharmacodynamics of drug use: An appraisal utilizing antibiotics. Advanced Drug Delivery Reviews, 2018, 123, 65-74.	6.6	46
132	Antibiotic Distribution into Cerebrospinal Fluid: Can Dosing Safely Account for Drug and Disease Factors in the Treatment of Ventriculostomy-Associated Infections?. Clinical Pharmacokinetics, 2018, 57, 439-454.	1.6	22
133	Prevalence of Augmented Renal Clearance and Performance of Glomerular Filtration Estimates in Indigenous Australian Patients Requiring Intensive Care Admission. Anaesthesia and Intensive Care, 2018, 46, 42-50.	0.2	12
134	A comparison between raw and predicted mortality in a paediatric intensive care unit in South Africa. BMC Research Notes, 2018, 11, 829.	0.6	7
135	The Statistical Curriculum Within Randomized Controlled Trials in Critical Illness*. Critical Care Medicine, 2018, 46, 1985-1990.	0.4	2
136	The authors reply. Critical Care Medicine, 2018, 46, e725-e726.	0.4	0
137	Strategies to Reduce Inappropriate Laboratory Blood Test Orders in Intensive Care Are Effective and Safe: A Before-And-After Quality Improvement Study. Anaesthesia and Intensive Care, 2018, 46, 313-320.	0.2	17
138	A research pathway for the study of the delivery and disposition of nebulised antibiotics: an incremental approach from in vitro to large animal models. Intensive Care Medicine Experimental, 2018, 6, 17.	0.9	7
139	Sepsis in Intensive Care Unit Patients: Worldwide Data From the Intensive Care over Nations Audit. Open Forum Infectious Diseases, 2018, 5, ofy313.	0.4	255
140	Patient and family engagement in the ICU: Report from the task force of the World Federation of Societies of Intensive and Critical Care Medicine. Journal of Critical Care, 2018, 48, 251-256.	1.0	76
141	Population pharmacokinetics of intravenous paracetamol in critically ill patients with traumatic brain injury. Journal of Critical Care, 2018, 47, 15-20.	1.0	5
142	A pharmacokinetic case study of intravenous posaconazole in a critically ill patient with hypoalbuminaemia receiving continuous venovenous haemodiafiltration. International Journal of Antimicrobial Agents, 2018, 52, 506-509.	1.1	7
143	Therapeutic drug monitoring of $\hat{l}^2$ -lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures. Journal of Antimicrobial Chemotherapy, 2018, 73, 3087-3094.	1.3	124
144	<i>Ex Vivo</i> Characterization of Effects of Renal Replacement Therapy Modalities and Settings on Pharmacokinetics of Meropenem and Vaborbactam. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	27

#	Article	IF	CITATIONS
145	New paradigm for rapid achievement of appropriate therapy in special populations: coupling antibiotic dose optimization rapid microbiological methods. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 693-708.	1.5	12
146	Optimised Dosing of Vancomycin in Critically Ill Indigenous Australian Patients with Severe Sepsis. Anaesthesia and Intensive Care, 2018, 46, 374-380.	0.2	9
147	Augmented Renal Clearance in Traumatic Brain Injury: A Single-Center Observational Study of Atrial Natriuretic Peptide, Cardiac Output, and Creatinine Clearance. Journal of Neurotrauma, 2017, 34, 137-144.	1.7	49
148	Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	54
149	The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship. Intensive Care Medicine, 2017, 43, 1187-1197.	3.9	103
150	Pyroglutamate (5-oxoproline) measured with hydrophilic interaction chromatography (HILIC) tandem mass spectrometry in acutely ill patients. Clinica Chimica Acta, 2017, 466, 72-77.	0.5	3
151	Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	34
152	Association between augmented renal clearance and clinical outcomes in patients receiving β-lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial. International Journal of Antimicrobial Agents, 2017, 49, 624-630.	1.1	80
153	Dosing antibiotic prophylaxis during cardiopulmonary bypassâ€"a higher level of complexity? A structured review. International Journal of Antimicrobial Agents, 2017, 49, 395-402.	1.1	25
154	"Salvage treatment―for infections by extensively- and pan-drug-resistant pathogens is common and often sub-optimal. Intensive Care Medicine, 2017, 43, 1164-1166.	3.9	6
155	Therapeutic targets in necrotizing soft tissue infections. Intensive Care Medicine, 2017, 43, 1717-1719.	3.9	8
156	Factors influencing psychological, social and health outcomes after major burn injuries in adults: cohort study protocol. BMJ Open, 2017, 7, e017545.	0.8	15
157	Comparative total and unbound pharmacokinetics of cefazolin administered by bolus versus continuous infusion in patients undergoing major surgery: a randomized controlled trial. British Journal of Anaesthesia, 2017, 118, 876-882.	1.5	25
158	Population Pharmacokinetics of Tigecycline in Critically III Patients with Severe Infections. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	42
159	Antibiotic dosing for multidrug-resistant pathogen pneumonia. Current Opinion in Infectious Diseases, 2017, 30, 231-239.	1.3	13
160	Right Dose, Right Now: Customized Drug Dosing in the Critically Ill. Critical Care Medicine, 2017, 45, 331-336.	0.4	55
161	What's new in pharmacokinetics of antimicrobials in AKI and RRT?. Intensive Care Medicine, 2017, 43, 904-906.	3.9	8
162	Impact of $\hat{l}^2$ -lactam antibiotic therapeutic drug monitoring on dose adjustments in critically ill patients undergoing continuous renal replacement therapy. International Journal of Antimicrobial Agents, 2017, 49, 589-594.	1.1	52

#	Article	IF	CITATIONS
163	Caspofungin Population Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-Venous Haemofiltration or Haemodiafiltration. Clinical Pharmacokinetics, 2017, 56, 1057-1068.	1.6	32
164	An LC–MS/MS method to determine vancomycin in plasma (total and unbound), urine and renal replacement therapy effluent. Bioanalysis, 2017, 9, 911-924.	0.6	17
165	Detailed assessment of benefits and risks of retrievable inferior vena cava filters on patients with complicated injuries: the da Vinci multicentre randomised controlled trial study protocol. BMJ Open, 2017, 7, e016747.	0.8	12
166	Using Population Pharmacokinetic Modeling and Monte Carlo Simulations To Determine whether Standard Doses of Piperacillin in Piperacillin-Tazobactam Regimens Are Adequate for the Management of Febrile Neutropenia. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	22
167	A validated UHPLC–MS/MS method for the measurement of riluzole in plasma and myocardial tissue samples. Biomedical Chromatography, 2017, 31, e4030.	0.8	1
168	Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients. International Journal of Antimicrobial Agents, 2017, 50, 227-231.	1.1	20
169	Hemoglobin concentrations and RBC transfusion thresholds in patients with acute brain injury: an international survey. Critical Care, 2017, 21, 159.	2.5	36
170	Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition. Clinical Microbiology and Infection, 2017, 23, 533-541.	2.8	58
171	Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a Hollow-Fiber Infection Model: Experimental Basis for Combination Therapy. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	22
172	Does Furosemide Increase Oxidative Stress in Acute Kidney Injury?. Antioxidants and Redox Signaling, 2017, 26, 221-226.	2.5	25
173	Interpretation of Care Guidelines for Obese Women in Labor: Intergroup Language and Social Identity. Journal of Language and Social Psychology, 2017, 36, 388-414.	1.2	1
174	Systemic Inflammatory Response Syndrome, Quick Sequential Organ Function Assessment, and Organ Dysfunction. Chest, 2017, 151, 586-596.	0.4	241
175	Identifying "at-risk―patients for sub-optimal beta-lactam exposure in critically ill patients with severe infections. Critical Care, 2017, 21, 283.	2.5	17
176	Anaesthetic Management of Obese Parturients: What is the Evidence Supporting Practice Guidelines?. Anaesthesia and Intensive Care, 2016, 44, 552-559.	0.2	5
177	Bugs, genes, and the intensive care unit. Journal of Thoracic Disease, 2016, 8, E788-E790.	0.6	1
178	Anaesthetists' Experiences with the Early Labour Epidural Recommendation for Obese Parturients: A Qualitative Study. Anaesthesia and Intensive Care, 2016, 44, 620-627.	0.2	3
179	Epha4-Fc Treatment Reduces Ischemia/Reperfusion-Induced Intestinal Injury by Inhibiting Vascular Permeability. Shock, 2016, 45, 184-191.	1.0	15
180	The Value of E-Learning for the Prevention of Healthcare-Associated Infections. Infection Control and Hospital Epidemiology, 2016, 37, 1052-1059.	1.0	22

#	Article	IF	Citations
181	Therapeutic drug monitoring of anti-infective agents in critically ill patients. Expert Review of Clinical Pharmacology, 2016, 9, 961-979.	1.3	98
182	Is inhaled prophylactic heparin useful for prevention and Management of Pneumonia in ventilated ICU patients?. Journal of Critical Care, 2016, 34, 95-102.	1.0	19
183	New Regimen for Continuous Infusion of Vancomycin in Critically III Patients. Antimicrobial Agents and Chemotherapy, 2016, 60, 4750-4756.	1.4	45
184	Effect of Obesity on the Population Pharmacokinetics of Meropenem in Critically Ill Patients. Antimicrobial Agents and Chemotherapy, 2016, 60, 4577-4584.	1.4	38
185	Determinants of Urinary Output Response to IV Furosemide in Acute Kidney Injury: A Pharmacokinetic/Pharmacodynamic Study. Critical Care Medicine, 2016, 44, e923-e929.	0.4	22
186	Is there a role for microsampling in antibiotic pharmacokinetic studies?. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 601-614.	1.5	20
187	In 2035, will all bacteria be multidrug-resistant? No. Intensive Care Medicine, 2016, 42, 2017-2020.	3.9	2
188	Should $\hat{l}^2$ -lactam antibiotics be administered by continuous infusion in critically ill patients? A survey of Australia and New Zealand intensive care unit doctors and pharmacists. International Journal of Antimicrobial Agents, 2016, 47, 436-438.	1.1	18
189	Effect of Obesity on the Population Pharmacokinetics of Fluconazole in Critically Ill Patients. Antimicrobial Agents and Chemotherapy, 2016, 60, 6550-6557.	1.4	38
190	Antibiotic dosing in obesity: a BIG challenge. Critical Care, 2016, 20, 240.	2.5	10
191	Problematic Dichotomization of Risk for Intensive Care Unit (ICU)–Acquired Invasive Candidiasis: Results Using a Risk-Predictive Model to Categorize 3 Levels of Risk From a Multicenter Prospective Cohort of Australian ICU Patients. Clinical Infectious Diseases, 2016, 63, 1463-1469.	2.9	36
192	Effect of time on recovery of plasma microsamples for the quantitative determination of vancomycin. Bioanalysis, 2016, 8, 2235-2242.	0.6	29
193	Sepsis: frontiers in diagnosis, resuscitation and antibiotic therapy. Intensive Care Medicine, 2016, 42, 1958-1969.	3.9	151
194	Optimising meropenem dosing in critically ill Australian Indigenous patients with severe sepsis. International Journal of Antimicrobial Agents, 2016, 48, 542-546.	1.1	30
195	Stability of Antibiotics for Intraperitoneal Administration in Extraneal 7.5% Icodextrin Peritoneal Dialysis Bags (Stab Study). Peritoneal Dialysis International, 2016, 36, 421-426.	1.1	11
196	Uncertainty in Antibiotic Dosing in Critically Ill Neonate and Pediatric Patients: Can Microsampling Provide the Answers?. Clinical Therapeutics, 2016, 38, 1961-1975.	1.1	31
197	Integrated pharmacokinetic–pharmacodynamic modelling to evaluate antimicrobial prophylaxis in abdominal surgery. Journal of Antimicrobial Chemotherapy, 2016, 71, 2902-2908.	1.3	12
198	Are new gentamicin dosing guidelines suitable for achieving target concentrations in patients with sepsis and septic shock?. Anaesthesia, Critical Care & Dain Medicine, 2016, 35, 311-312.	0.6	2

#	Article	IF	CITATIONS
199	Pharmacokinetics of Piperacillin in Critically Ill Australian Indigenous Patients with Severe Sepsis. Antimicrobial Agents and Chemotherapy, 2016, 60, 7402-7406.	1.4	14
200	Total and unbound ceftriaxone pharmacokinetics in critically ill Australian Indigenous patients with severe sepsis. International Journal of Antimicrobial Agents, 2016, 48, 748-752.	1,1	22
201	Determination of Cefalothin and Cefazolin in Human Plasma, Urine and Peritoneal Dialysate by UHPLCâ€MS/MS: application to a pilot pharmacokinetic study in humans. Biomedical Chromatography, 2016, 30, 872-879.	0.8	22
202	We need to optimize piperacillin-tazobactam dosing in critically ill patientsâ€"but how?. Critical Care, 2016, 20, 163.	2.5	6
203	"Not out of the woodsâ€â€"a wife's perspective: bedside communication. Intensive Care Medicine, 2016, 42, 446-447.	3.9	4
204	Effect of different renal function on antibacterial effects of piperacillin against <i>Pseudomonas aeruginosa</i> evaluated via the hollow-fibre infection model and mechanism-based modelling. Journal of Antimicrobial Chemotherapy, 2016, 71, 2509-2520.	1.3	38
205	CAMERA2 â€" combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial. Trials, 2016, 17, 170.	0.7	61
206	Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically III Patients on Continuous Renal Replacement Therapy. Antimicrobial Agents and Chemotherapy, 2016, 60, 4901-4909.	1.4	29
207	Severity Scores in Emergency Department Patients With Presumed Infection. Critical Care Medicine, 2016, 44, 539-547.	0.4	42
208	Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. Intensive Care Medicine, 2016, 42, 1535-1545.	3.9	244
209	Pharmacokinetics of Intraperitoneal Cefalothin and Cefazolin in Patients Being Treated for Peritoneal Dialysis-Associated Peritonitis. Peritoneal Dialysis International, 2016, 36, 415-420.	1.1	7
210	What is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients?. Journal of Antimicrobial Chemotherapy, 2016, 71, 696-702.	1.3	37
211	<i>In Vivo</i> Microdialysis To Determine Subcutaneous Interstitial Fluid Penetration and Pharmacokinetics of Fluconazole in Intensive Care Unit Patients with Sepsis. Antimicrobial Agents and Chemotherapy, 2016, 60, 827-832.	1.4	18
212	Continuous versus Intermittent $\hat{I}^2$ -Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 681-691.	2.5	308
213	Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: A structured review. International Journal of Antimicrobial Agents, 2016, 47, 259-268.	1.1	94
214	The use and risks of antibiotics in critically ill patients. Expert Opinion on Drug Safety, 2016, 15, 667-678.	1.0	25
215	SaMpling Antibiotics in Renal Replacement Therapy (SMARRT): an observational pharmacokinetic study in critically ill patients. BMC Infectious Diseases, 2016, 16, 103.	1.3	14
216	Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients. Journal of Antimicrobial Chemotherapy, 2016, 71, 1643-1650.	1.3	16

#	Article	IF	Citations
217	A Systematic Review of the Definitions, Determinants, and Clinical Outcomes of Antimicrobial De-escalation in the Intensive Care Unit. Clinical Infectious Diseases, 2016, 62, 1009-1017.	2.9	168
218	Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration. Journal of Antimicrobial Chemotherapy, 2016, 71, 464-470.	1.3	36
219	Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. Journal of Antimicrobial Chemotherapy, 2016, 71, 196-207.	1.3	129
220	Population Pharmacokinetics of Doripenem in Critically Ill Patients with Sepsis in a Malaysian Intensive Care Unit. Antimicrobial Agents and Chemotherapy, 2016, 60, 206-214.	1.4	11
221	Understanding PK/PD. Intensive Care Medicine, 2016, 42, 1797-1800.	3.9	64
222	Use of neostigmine for acute colonic pseudo-obstruction in a patient receiving dexmedetomidine. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2016, 18, 59-61.	0.0	1
223	Is high-dose $\hat{I}^2$ -lactam therapy associated with excessive drug toxicity in critically ill patients?. Minerva Anestesiologica, 2016, 82, 957-65.	0.6	25
224	Can We Use an Ex Vivo Continuous Hemofiltration Model to Describe the Adsorption and Elimination of Meropenem and Piperacillin?. International Journal of Artificial Organs, 2015, 38, 419-424.	0.7	13
225	Pharmacokinetic/pharmacodynamic considerations for the optimization of antimicrobial delivery in the critically ill. Current Opinion in Critical Care, 2015, 21, 412-420.	1.6	75
226	Does Appropriate Antibiotic Therapy Mean Only Adequate Spectrum and Timing?*. Critical Care Medicine, 2015, 43, 1773-1774.	0.4	6
227	Antibiotic administration in the critically ill - in need of intensive care!. South African Medical Journal, 2015, 105, 357.	0.2	4
228	A Molecular Host Response Assay to Discriminate Between Sepsis and Infection-Negative Systemic Inflammation in Critically Ill Patients: Discovery and Validation in Independent Cohorts. PLoS Medicine, 2015, 12, e1001916.	3.9	163
229	The Effect of Paracetamol on Core Body Temperature in Acute Traumatic Brain Injury: A Randomised, Controlled Clinical Trial. PLoS ONE, 2015, 10, e0144740.	1.1	24
230	Factors Associated with Vancomycin Nephrotoxicity in the Critically III. Anaesthesia and Intensive Care, 2015, 43, 594-599.	0.2	45
231	Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?. Critical Care, 2015, 19, 28.	2.5	111
232	Subtleties in practical application of prolonged infusion of $\hat{l}^2$ -lactam antibiotics. International Journal of Antimicrobial Agents, 2015, 45, 461-463.	1,1	36
233	A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Critical Care, 2015, 19, 84.	2.5	108
234	Quantitative bioanalytical validation of fosfomycin in human whole blood with volumetric absorptive microsampling. Bioanalysis, 2015, 7, 2585-2595.	0.6	45

#	Article	IF	Citations
235	To increase or decrease dosage of antimicrobials in septic patients during continuous renal replacement therapy: the eternal doubt. Current Opinion in Pharmacology, 2015, 24, 68-78.	1.7	28
236	Antibiotic dose optimization in critically ill patients. Medicina Intensiva (English Edition), 2015, 39, 563-572.	0.1	2
237	Pharmacokinetics of fluconazole in critically ill patients with acute kidney injury receiving sustained low-efficiency diafiltration. International Journal of Antimicrobial Agents, 2015, 45, 192-195.	1.1	8
238	Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: A randomised controlled trial of continuous infusion versus intermittent bolus administration. International Journal of Antimicrobial Agents, 2015, 45, 41-45.	1.1	50
239	Comparison of the Accuracy and Precision of Pharmacokinetic Equations To Predict Free Meropenem Concentrations in Critically Ill Patients. Antimicrobial Agents and Chemotherapy, 2015, 59, 1411-1417.	1.4	26
240	Are interstitial fluid concentrations of meropenem equivalent to plasma concentrations in critically ill patients receiving continuous renal replacement therapy?. Journal of Antimicrobial Chemotherapy, 2015, 70, 528-533.	1.3	21
241	How can we ensure effective antibiotic dosing in critically ill patients receiving different types of renal replacement therapy?. Diagnostic Microbiology and Infectious Disease, 2015, 82, 92-103.	0.8	68
242	The Durban World Congress Ethics Round Table IV: Health care professional end-of-life decision making. Journal of Critical Care, 2015, 30, 224-230.	1.0	27
243	Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients. Journal of Antimicrobial Chemotherapy, 2015, 70, 1495-1502.	1.3	60
244	Candida Colonization as a Risk Marker for Invasive Candidiasis in Mixed Medical-Surgical Intensive Care Units: Development and Evaluation of a Simple, Standard Protocol. Journal of Clinical Microbiology, 2015, 53, 1324-1330.	1.8	44
245	From the intensive care bed: we need to hear and listen. Intensive Care Medicine, 2015, 41, 921-922.	3.9	1
246	A meta-analysis of ventriculostomy-associated cerebrospinal fluid infections. BMC Infectious Diseases, 2015, 15, 3.	1.3	118
247	Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study. Critical Care, 2015, 19, 33.	2.5	108
248	Pharmacokinetics of piperacillin in critically ill patients receiving continuous venovenous haemofiltration: A randomised controlled trial of continuous infusion versus intermittent bolus administration. International Journal of Antimicrobial Agents, 2015, 46, 39-44.	1.1	28
249	Influence of sustained low-efficiency diafiltration (SLED-f) on interstitial fluid concentrations of fluconazole in a critically ill patient: Use of microdialysis. International Journal of Antimicrobial Agents, 2015, 46, 121-124.	1.1	6
250	A Simulation Study Reveals Lack of Pharmacokinetic/Pharmacodynamic Target Attainment in De-escalated Antibiotic Therapy in Critically Ill Patients. Antimicrobial Agents and Chemotherapy, 2015, 59, 4689-4694.	1.4	19
251	A validated method for the quantification of fosfomycin on dried plasma spots by HPLC–MS/MS: Application to a pilot pharmacokinetic study in humans. Journal of Pharmaceutical and Biomedical Analysis, 2015, 115, 509-514.	1.4	23
252	A Multicenter Randomized Trial of Continuous versus Intermittent $\hat{I}^2$ -Lactam Infusion in Severe Sepsis. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1298-1305.	2.5	206

#	Article	IF	CITATIONS
253	The authors reply. Critical Care Medicine, 2015, 43, e101-e102.	0.4	0
254	Vancomycin-associated nephrotoxicity: A meta-analysis of administration by continuous versus intermittent infusion. International Journal of Antimicrobial Agents, 2015, 46, 249-253.	1.1	56
255	Augmented renal clearance and therapeutic monitoring of $\hat{l}^2$ -lactams. International Journal of Antimicrobial Agents, 2015, 45, 331-333.	1.1	26
256	Therapeutic drug monitoring of the $\hat{l}^2$ -lactam antibiotics: what is the evidence and which patients should we be using it for?: FigureÂ1 Journal of Antimicrobial Chemotherapy, 2015, 70, dkv201.	1.3	118
257	The ADMIN-ICU survey: a survey on antimicrobial dosing and monitoring in ICUs. Journal of Antimicrobial Chemotherapy, 2015, 70, 2671-2677.	1.3	106
258	The authors reply. Critical Care Medicine, 2015, 43, e154-e155.	0.4	1
259	Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial. Trials, 2015, 16, 24.	0.7	57
260	Even high-dose extended infusions may not yield desired concentrations of $\hat{l}^2$ -lactams: the value of therapeutic drug monitoring. Infectious Diseases, 2015, 47, 739-742.	1.4	8
261	Applying Pharmacokinetic/Pharmacodynamic Principles in Critically Ill Patients: Optimizing Efficacy and Reducing Resistance Development. Seminars in Respiratory and Critical Care Medicine, 2015, 36, 136-153.	0.8	134
262	The Impact of Hospital and ICU Organizational Factors on Outcome in Critically Ill Patients. Critical Care Medicine, 2015, 43, 519-526.	0.4	170
263	Albumin concentration significantly impacts on free teicoplanin plasma concentrations in non-critically ill patients with chronic bone sepsis. International Journal of Antimicrobial Agents, 2015, 45, 647-651.	1.1	20
264	An UHPLC–MS/MS method for the simultaneous determination of ampicillin and sulbactam in human plasma and urine. Bioanalysis, 2015, 7, 2311-2319.	0.6	9
265	Antibiotic dose optimization in critically ill patients. Medicina Intensiva, 2015, 39, 563-572.	0.4	39
266	Assays for therapeutic drug monitoring of $\hat{l}^2$ -lactam antibiotics: A structured review. International Journal of Antimicrobial Agents, 2015, 46, 367-375.	1.1	95
267	Population Pharmacokinetics of Fosfomycin in Critically III Patients. Antimicrobial Agents and Chemotherapy, 2015, 59, 6471-6476.	1.4	59
268	A simple LC–MS/MS method using HILIC chromatography for the determination of fosfomycin in plasma and urine: Application to a pilot pharmacokinetic study in humans. Journal of Pharmaceutical and Biomedical Analysis, 2015, 105, 39-45.	1.4	28
269	Interethnic Differences in Pharmacokinetics of Antibacterials. Clinical Pharmacokinetics, 2015, 54, 243-260.	1.6	36
270	Tracheal Cuff Pressure Monitoring in the ICU: A Literature Review and Survey of Current Practice in Queensland. Anaesthesia and Intensive Care, 2014, 42, 761-770.	0.2	27

#	Article	IF	Citations
271	Select Critically ill Patients at Risk of Augmented Renal Clearance: Experience in a Malaysian Intensive Care Unit. Anaesthesia and Intensive Care, 2014, 42, 715-722.	0.2	26
272	How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?. BMC Infectious Diseases, 2014, 14, 288.	1.3	83
273	Low Flucloxacillin Concentrations in a Patient With Central Nervous System Infection. Annals of Pharmacotherapy, 2014, 48, 1380-1384.	0.9	20
274	Antimicrobial stewardship of $\hat{l}^2$ -lactams in intensive care units. Expert Review of Anti-Infective Therapy, 2014, 12, 581-595.	2.0	12
275	The effect of pathophysiology on pharmacokinetics in the critically ill patient â€" Concepts appraised by the example of antimicrobial agents. Advanced Drug Delivery Reviews, 2014, 77, 3-11.	6.6	351
276	Infections, antibiotic treatment and mortality in patients admitted to ICUs in countries considered to have high levels of antibiotic resistance compared to those with low levels. BMC Infectious Diseases, 2014, 14, 513.	1.3	20
277	The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study. Critical Care, 2014, 18, 565.	2.5	87
278	Determining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds. Critical Care, 2014, 18, 657.	2.5	64
279	Burn Resuscitationâ€"Hourly Urine Output Versus Alternative Endpoints. Shock, 2014, 42, 295-306.	1.0	57
280	The Impact of Variation in Renal Replacement Therapy Settings on Piperacillin, Meropenem, and Vancomycin Drug Clearance in the Critically III. Critical Care Medicine, 2014, 42, 1640-1650.	0.4	103
281	Vancomycin-Associated Nephrotoxicity in the Critically Ill. Critical Care Medicine, 2014, 42, 2527-2536.	0.4	94
282	Augmented Renal Clearance in the ICU. Critical Care Medicine, 2014, 42, 520-527.	0.4	232
283	A New Marker of Sepsis Post Burn Injury?*. Critical Care Medicine, 2014, 42, 2029-2036.	0.4	35
284	Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration. Journal of Antimicrobial Chemotherapy, 2014, 69, 2508-2516.	1.3	29
285	Assessment of the worldwide burden of critical illness: the Intensive Care Over Nations (ICON) audit. Lancet Respiratory Medicine, the, 2014, 2, 380-386.	5.2	864
286	Seated and semi-recumbent positioning of the ventilated intensive care patient – Effect on gas exchange, respiratory mechanics and hemodynamics. Heart and Lung: Journal of Acute and Critical Care, 2014, 43, 105-111.	0.8	16
287	Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infectious Diseases, The, 2014, 14, 498-509.	4.6	745
288	Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: Lessons from the DALI Study. International Journal of Antimicrobial Agents, 2014, 43, 423-430.	1,1	48

#	Article	IF	Citations
289	The influence of acute kidney injury on antimicrobial dosing in critically ill patients: are dose reductions always necessary?. Diagnostic Microbiology and Infectious Disease, 2014, 79, 77-84.	0.8	50
290	A national survey of renal replacement therapy prescribing practice for acute kidney injury in <scp>M</scp> alaysian intensive care units. Nephrology, 2014, 19, 507-512.	0.7	11
291	Altered Pharmacokinetics of Piperacillin in Febrile Neutropenic Patients with Hematological Malignancy. Antimicrobial Agents and Chemotherapy, 2014, 58, 3533-3537.	1.4	37
292	An international, multicentre survey of $\hat{A}$ -lactam antibiotic therapeutic drug monitoring practice in intensive care units. Journal of Antimicrobial Chemotherapy, 2014, 69, 1416-1423.	1.3	185
293	DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current Â-Lactam Antibiotic Doses Sufficient for Critically Ill Patients?. Clinical Infectious Diseases, 2014, 58, 1072-1083.	2.9	843
294	Plasma and cerebrospinal fluid concentrations of linezolid in neurosurgical critically ill patients with proven or suspected central nervous system infections. International Journal of Antimicrobial Agents, 2014, 44, 409-415.	1.1	47
295	The Durban World Congress Ethics Round Table Conference Report: I. Differences between withholding and withdrawing life-sustaining treatments. Journal of Critical Care, 2014, 29, 890-895.	1.0	35
296	Reply to Rhodes et al. Clinical Infectious Diseases, 2014, 59, 907-908.	2.9	2
297	Abdominal infections in the intensive care unit: characteristics, treatment and determinants of outcome. BMC Infectious Diseases, 2014, 14, 420.	1.3	88
298	Risk factors for target non-attainment during empirical treatment with $\hat{l}^2$ -lactam antibiotics in critically ill patients. Intensive Care Medicine, 2014, 40, 1340-1351.	3.9	147
299	The Durban World Congress Ethics Round Table Conference Report: II. Withholding or withdrawing of treatment in elderly patients admitted to the intensive care unit. Journal of Critical Care, 2014, 29, 896-901.	1.0	32
300	Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study. Critical Care, 2014, 18, R99.	2.5	87
301	Pharmacokinetics of piperacillin and tazobactam in plasma and subcutaneous interstitial fluid in critically ill patients receiving continuous venovenous haemodiafiltration. International Journal of Antimicrobial Agents, 2014, 43, 343-348.	1.1	45
302	Infections and Use of Antibiotics in Patients Admitted for Severe Acute Pancreatitis: Data from the EPIC II Study. Surgical Infections, 2014, 15, 394-398.	0.7	24
303	Population pharmacokinetics and dose simulation of vancomycin in critically ill patients during high-volume haemofiltration. International Journal of Antimicrobial Agents, 2014, 44, 163-167.	1.1	27
304	Variable ganciclovir concentrations in a critically ill patient receiving continuous renal replacement therapy and plasma exchange?. International Journal of Antimicrobial Agents, 2014, 43, 570-571.	1.1	8
305	Population pharmacokinetics and dosing simulations of cefuroxime in critically ill patients: non-standard dosing approaches are required to achieve therapeutic exposures. Journal of Antimicrobial Chemotherapy, 2014, 69, 2797-2803.	1.3	30
306	The Durban World Congress Ethics Round Table Conference Report: III. Withdrawing Mechanical ventilation—the approach should be individualized. Journal of Critical Care, 2014, 29, 902-907.	1.0	32

#	Article	IF	Citations
307	The authors reply. Critical Care Medicine, 2014, 42, e675-e676.	0.4	0
308	The authors reply. Critical Care Medicine, 2014, 42, e602-e603.	0.4	0
309	Principles of antibiotic use. , 2014, , 738-742.e1.		0
310	Extended versus bolus infusion of meropenem and piperacillin: a pharmacokinetic analysis. Minerva Anestesiologica, 2014, 80, 1302-9.	0.6	26
311	Randomised controlled trials: the long hard climb to the summit-is there another way in the 21st century?. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2014, 16, 87-9.	0.0	0
312	Clinical measures for increased creatinine clearances and suboptimal antibiotic dosing. Intensive Care Medicine, 2013, 39, 1322-1324.	3.9	13
313	Antibiotic prescription for respiratory tract infections in ventilated patients: where are we heading?. Intensive Care Medicine, 2013, 39, 1644-1646.	3.9	4
314	What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review. International Journal of Antimicrobial Agents, 2013, 42, 289-293.	1.1	63
315	Population pharmacokinetics and dosing simulations of amoxicillin/clavulanic acid in critically ill patients. Journal of Antimicrobial Chemotherapy, 2013, 68, 2600-2608.	1.3	48
316	Protein Binding of $\hat{I}^2$ -Lactam Antibiotics in Critically III Patients: Can We Successfully Predict Unbound Concentrations?. Antimicrobial Agents and Chemotherapy, 2013, 57, 6165-6170.	1.4	185
317	Reply to Soman et al. Clinical Infectious Diseases, 2013, 57, 323-324.	2.9	0
318	A comparison of CKD-EPI estimated glomerular filtration rate and measured creatinine clearance in recently admitted critically ill patients with normal plasma creatinine concentrations. BMC Nephrology, 2013, 14, 250.	0.8	48
319	Clinical implications of antibiotic pharmacokinetic principles in the critically ill. Intensive Care Medicine, 2013, 39, 2070-2082.	3.9	192
320	Ampicillin/sulbactam: Its potential use in treating infections in critically ill patients. International Journal of Antimicrobial Agents, 2013, 42, 384-389.	1.1	53
321	The Clinical Relevance of Plasma Protein Binding Changes. Clinical Pharmacokinetics, 2013, 52, 1-8.	1.6	225
322	Continuous Infusion of Beta-Lactam Antibiotics in Severe Sepsis: A Multicenter Double-Blind, Randomized Controlled Trial. Clinical Infectious Diseases, 2013, 56, 236-244.	2.9	317
323	$\hat{l}^2$ -Lactam therapeutic drug monitoring in the critically ill: optimising drug exposure in patients with fluctuating renal function and hypoalbuminaemia. International Journal of Antimicrobial Agents, 2013, 41, 162-166.	1.1	65
324	Pharmacokinetics of meropenem and piperacillin in critically ill patients with indwelling surgical drains. International Journal of Antimicrobial Agents, 2013, 42, 90-93.	1.1	24

#	Article	IF	CITATIONS
325	Can population pharmacokinetic modelling guide vancomycin dosing during continuous renal replacement therapy in critically ill patients?. International Journal of Antimicrobial Agents, 2013, 41, 564-568.	1.1	44
326	Augmented renal clearance in septic and traumatized patients with normal plasma creatinine concentrations: identifying at-risk patients. Critical Care, 2013, 17, R35.	2.5	149
327	Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?. Critical Care, 2013, 17, R84.	2.5	166
328	Molecular Analysis of the Acinetobacter baumannii Biofilm-Associated Protein. Applied and Environmental Microbiology, 2013, 79, 6535-6543.	1.4	68
329	B-Type Natriuretic Peptide. A & A Case Reports, 2013, 1, 59-61.	0.7	0
330	A Protocol for the Pharmacokinetics of Enteric Coated Mycophenolate Sodium in Lupus Nephritis (POEMSLUN): an open-label, randomised controlled trial. BMJ Open, 2013, 3, e003511.	0.8	2
331	How should we dose antibiotics for pneumonia in the ICU?. Current Opinion in Infectious Diseases, 2013, 26, 189-195.	1.3	10
332	Toward Improved Surveillance: The Impact of Ventilator-Associated Complications on Length of Stay and Antibiotic Use in Patients in Intensive Care Units. Clinical Infectious Diseases, 2013, 56, 471-477.	2.9	141
333	Antibacterial therapeutic drug monitoring in cerebrospinal fluid: difficulty in achieving adequate drug concentrations. Journal of Neurosurgery, 2013, 118, 297-301.	0.9	38
334	Defining Antibiotic Dosing in Lung Infections. Clinical Pulmonary Medicine, 2013, 20, 121-128.	0.3	18
335	A new regimen for continuous infusion of vancomycin during continuous renal replacement therapy. Journal of Antimicrobial Chemotherapy, 2013, 68, 2859-2865.	1.3	52
336	Optimal Doripenem Dosing Simulations in Critically III Nosocomial Pneumonia Patients With Obesity, Augmented Renal Clearance, and Decreased Bacterial Susceptibility*. Critical Care Medicine, 2013, 41, 489-495.	0.4	81
337	Identification of Novel Vaccine Candidates against Multidrug-Resistant Acinetobacter baumannii. PLoS ONE, 2013, 8, e77631.	1.1	80
338	Phenytoin Loading Doses in Adult Critical Care Patients: Does Current Practice Achieve Adequate Drug Levels?. Anaesthesia and Intensive Care, 2013, 41, 602-609.	0.2	5
339	A protocol for a multicentre randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients with severe sepsis: the BLING II study. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2013. 15. 179-85.	0.0	3
340	Improving antibiotic dosing in special situations in the ICU. Current Opinion in Critical Care, 2012, 18, 460-471.	1.6	86
341	Pharmacokinetics of Intraperitoneal Gentamicin in Peritoneal Dialysis Patients with Peritonitis (GIPD) Tj ETQq $1\ 1$	0.784314 2.2	rgBT /Overlo
342	Therapeutic Drug Monitoring of Beta-Lactam Antibiotics in Burns Patients—A One-Year Prospective Study. Therapeutic Drug Monitoring, 2012, 34, 160-164.	1.0	65

#	Article	IF	Citations
343	Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy. Critical Care Medicine, 2012, 40, 1523-1528.	0.4	185
344	Subtherapeutic Initial $\hat{I}^2$ -Lactam Concentrations in Select Critically III Patients. Chest, 2012, 142, 30-39.	0.4	354
345	Hydroxyethyl Starch or Saline for Fluid Resuscitation in Intensive Care. New England Journal of Medicine, 2012, 367, 1901-1911.	13.9	1,460
346	Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study. Intensive Care Medicine, 2012, 38, 1930-1945.	3.9	322
347	A limited set of molecular biomarkers may provide superior diagnostic outcomes to procalcitonin in sepsis. Critical Care, $2012, 16, .$	2.5	1
348	Characteristics of bloodstream infections in burn patients: An 11-year retrospective study. Burns, 2012, 38, 685-690.	1.1	53
349	DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic. BMC Infectious Diseases, 2012, 12, 152.	1.3	47
350	Using pharmacokinetics and pharmacodynamics to optimise dosing of antifungal agents in critically ill patients: a systematic review. International Journal of Antimicrobial Agents, 2012, 39, 1-10.	1.1	45
351	Improving vancomycin prescription in critical illness through a drug use evaluation process: a weight-based dosing intervention study. International Journal of Antimicrobial Agents, 2012, 39, 69-72.	1.1	47
352	How to optimise antimicrobial prescriptions in the Intensive Care Unit: principles of individualised dosing using pharmacokinetics and pharmacodynamics. International Journal of Antimicrobial Agents, 2012, 39, 187-192.	1.1	62
353	What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance. International Journal of Antimicrobial Agents, 2012, 39, 455-457.	1.1	84
354	A method for determining the free (unbound) concentration of ten beta-lactam antibiotics in human plasma using high performance liquid chromatography with ultraviolet detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 907, 178-184.	1.2	107
355	Pharmacokinetics of Beta-Lactam Antibiotics in Patients with Intra-Abdominal Disease: A Structured Review. Surgical Infections, 2012, 13, 9-17.	0.7	27
356	Editorial Commentary: Closing the LoopA Colistin Clinical Study to Confirm Dosing Recommendations From PK/PD Modeling. Clinical Infectious Diseases, 2012, 54, 1727-1729.	2.9	20
357	Sepsis Management., 2012, , .		1
358	Continuous beta-lactam infusion in critically ill patients: the clinical evidence. Annals of Intensive Care, 2012, 2, 37.	2.2	85
359	Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review. Annals of Intensive Care, 2012, 2, 35.	2.2	149
360	Blood Culture Collection in Patients with Acute Kidney Injury Receiving Renal Replacement Therapy: An Observational Study. Anaesthesia and Intensive Care, 2012, 40, 813-819.	0.2	3

#	Article	IF	Citations
361	A Comparison of Pulse Contour Wave Analysis and Ultrasonic Cardiac Output Monitoring in the Critically III. Anaesthesia and Intensive Care, 2012, 40, 631-637.	0.2	9
362	Importance of High Creatinine Clearance for Antibacterial Treatment in Sepsis., 2012, , 171-197.		0
363	Review article: Part two: Goalâ€directed resuscitation – Which goals? Perfusion targets. EMA - Emergency Medicine Australasia, 2012, 24, 127-135.	0.5	13
364	Review article: Part one: Goalâ€directed resuscitation – Which goals? Haemodynamic targets. EMA - Emergency Medicine Australasia, 2012, 24, 14-22.	0.5	15
365	l̂²â€≺scp>Lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: A structured review. Clinical and Experimental Pharmacology and Physiology, 2012, 39, 489-496.	0.9	74
366	The Ecology of Antibiotic Use in the ICU: Homogeneous Prescribing of Cefepime but Not Tazocin Selects for Antibiotic Resistant Infection. PLoS ONE, 2012, 7, e38719.	1.1	23
367	Antibiotic Therapy of Pneumonia in Critical Care. Current Respiratory Medicine Reviews, 2012, 8, 228-238.	0.1	0
368	Continuous infusion vs. bolus dosing: implications for beta-lactam antibiotics. Minerva Anestesiologica, 2012, 78, 94-104.	0.6	29
369	Therapeutic drug monitoring when using cefepime in continuous renal replacement therapy: seizures associated with cefepime. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2012, 14, 312-5.	0.0	14
370	A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance. Critical Care, 2011, 15, R139.	2.5	174
371	Development and validation of a novel molecular biomarker diagnostic test for the early detection of sepsis. Critical Care, 2011, 15, R149.	2.5	141
372	Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients. Journal of Antimicrobial Chemotherapy, 2011, 66, 227-231.	1.3	119
373	Ganciclovir pharmacokinetics and suggested dosing in continuous venovenous haemodiafiltration. International Journal of Antimicrobial Agents, 2011, 37, 90-92.	1.1	7
374	Increased mortality associated with meticillin-resistant Staphylococcus aureus (MRSA) infection in the Intensive Care Unit: results from the EPIC II study. International Journal of Antimicrobial Agents, 2011, 38, 331-335.	1.1	145
375	Antimicrobial Pharmacokinetic and Pharmacodynamic Issues in the Critically III with Severe Sepsis and Septic Shock. Critical Care Clinics, 2011, 27, 19-34.	1.0	118
376	The Effects of Hypoalbuminaemia on Optimizing Antibacterial Dosing in Critically III Patients. Clinical Pharmacokinetics, 2011, 50, 99-110.	1.6	325
377	Pharmacokinetic evaluation of fluconazole in critically ill patients. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 1431-1440.	1.5	13
378	Antimicrobial Utilisation in 37 Australian and New Zealand Intensive Care Units. Anaesthesia and Intensive Care, 2011, 39, 231-237.	0.2	28

#	Article	lF	CITATIONS
379	The Critical Care Costs of the Influenza A/H1N1 2009 Pandemic in Australia and New Zealand. Anaesthesia and Intensive Care, 2011, 39, 384-391.	0.2	21
380	Do We Understand the Impact of Altered Physiology, Consequent Interventions and Resultant Clinical Scenarios in the Intensive Care Unit? the Antibiotic Story. Anaesthesia and Intensive Care, 2011, 39, 999-1000.	0.2	39
381	Experience with High Frequency Oscillation Ventilation during the 2009 H1N1 Influenza Pandemic in Australia and New Zealand. Anaesthesia and Intensive Care, 2011, 39, 837-846.	0.2	7
382	Sustained low efficiency dialysis allows rational renal replacement therapy, but does it allow rational drug dosing?*. Critical Care Medicine, 2011, 39, 602-603.	0.4	20
383	Determining authorship in multicenter trials: a systematic review. Acta Anaesthesiologica Scandinavica, 2011, 55, 1037-1043.	0.7	21
384	Pitfalls of using estimations of glomerular filtration rate in an intensive care population. Internal Medicine Journal, 2011, 41, 537-543.	0.5	69
385	Prior Statin Use Is Not Associated With Improved Outcome in Emergency Patients Admitted With Infection: A Prospective Observational Study. Academic Emergency Medicine, 2011, 18, 127-134.	0.8	8
386	Implications of augmented renal clearance in critically ill patients. Nature Reviews Nephrology, 2011, 7, 539-543.	4.1	169
387	The role of surveillance cultures in the prediction of susceptibility patterns of Gram-negative bacilli in the intensive care unit. European Journal of Clinical Microbiology and Infectious Diseases, 2011, 30, 739-744.	1.3	16
388	The Crystalloid versus Hydroxyethyl Starch Trial: protocol for a multi-centre randomised controlled trial of fluid resuscitation with 6% hydroxyethyl starch (130/0.4) compared to 0.9% sodium chloride (saline) in intensive care patients on mortality. Intensive Care Medicine, 2011, 37, 816-823.	3.9	34
389	Antibiotic dosing in the 'at risk' critically ill patient: Linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients. BMC Anesthesiology, 2011, 11, 3.	0.7	43
390	The pharmacokinetics of cefazolin in patients undergoing elective & Department among the pharmacokinetics of cefazolin in patients undergoing elective & Department among the pharmacokinetics of cefazolin in patients undergoing elective & Department among the pharmacokinetics of cefazolin in patients undergoing elective & Department among the pharmacokinetics of cefazolin in patients undergoing elective & Department among the pharmacokinetics of cefazolin in patients undergoing elective & Department among the pharmacokinetics of cefazolin in patients undergoing elective & Department among the pharmacokinetics of cefazolin in patients undergoing elective & Department among the pharmacokinetics of cefazolin in patients undergoing elective & Department among the pharmacokinetics of cefazolin in patients undergoing elective & Department among the pharmacokinetics of cefazolin in patients among the pharmacokinetics among the pharmacokinetics of cefazolin in patients among the pharmacokinetics among the pharmacokinetics of cefazolin in patients among the pharmacokinetics among the pha	0.7	7
391	A prospective registry of emergency department patients admitted with infection. BMC Infectious Diseases, 2011, 11, 27.	1.3	9
392	Physiological Changes in the Critically III Patient with Sepsis. Current Pharmaceutical Biotechnology, 2011, 12, 1991-1995.	0.9	33
393	ARC - Augmented Renal Clearance. Current Pharmaceutical Biotechnology, 2011, 12, 2020-2029.	0.9	38
394	Remote care by telemedicine in the ICU. Current Opinion in Critical Care, 2011, 17, 634-640.	1.6	20
395	Plasma and Tissue Pharmacokinetics of Cefazolin in Patients Undergoing Elective and Semielective Abdominal Aortic Aneurysm Open Repair Surgery. Antimicrobial Agents and Chemotherapy, 2011, 55, 5238-5242.	1.4	68
396	Antibiotic Dosing in Multiple Organ Dysfunction Syndrome. Chest, 2011, 139, 1210-1220.	0.4	80

#	Article	IF	Citations
397	Effect of intravenous GLutamine supplementation IN Trauma patients receiving enteral nutrition study protocol (GLINT Study): a prospective, blinded, randomised, placebo-controlled clinical trial. BMJ Open, 2011, 1, e000334-e000334.	0.8	11
398	Population Pharmacokinetics of Fluconazole in Critically Ill Patients Receiving Continuous Venovenous Hemodiafiltration: Using Monte Carlo Simulations To Predict Doses for Specified Pharmacodynamic Targets. Antimicrobial Agents and Chemotherapy, 2011, 55, 5868-5873.	1.4	48
399	Vancomycin Dosing in Critically Ill Patients: Robust Methods for Improved Continuous-Infusion Regimens. Antimicrobial Agents and Chemotherapy, 2011, 55, 2704-2709.	1.4	197
400	Candida Pneumonia in Patients with Hematological Neoplasia. , 2011, , 349-356.		1
401	Preventive Strategies for Ventilator Associated Pneumonia. Current Respiratory Medicine Reviews, 2010, 6, 238-252.	0.1	4
402	Optimizing Antibiotic Use in the Intensive Care Unit. Clinical Pulmonary Medicine, 2010, 17, 162-169.	0.3	1
403	Prophylaxis, empirical and preemptive treatment of invasive candidiasis. Current Opinion in Critical Care, 2010, 16, 470-474.	1.6	28
404	Pharmacokinetics and pharmacodynamics in critically ill patients. Current Opinion in Anaesthesiology, 2010, 23, 472-478.	0.9	49
405	Do Burn Patients Cost More? The Intensive Care Unit Costs of Burn Patients Compared With Controls Matched for Length of Stay and Acuity. Journal of Burn Care and Research, 2010, 31, 598-602.	0.2	26
406	Augmented Creatinine Clearance in Traumatic Brain Injury. Anesthesia and Analgesia, 2010, 111, 1505-1510.	1.1	105
407	Assessment of peripheral arterial catheters as a source of sepsis in the critically ill: a narrative review. Journal of Hospital Infection, 2010, 75, 12-18.	1.4	30
408	Analysis of 12 beta-lactam antibiotics in human plasma by HPLC with ultraviolet detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 2039-2043.	1.2	172
409	Can Learning to Sustain Life be BASIC? Teaching for the Initial Management of the Critically Ill in Australia and New Zealand. Anaesthesia and Intensive Care, 2010, 38, 1043-1051.	0.2	4
410	Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics. Journal of Antimicrobial Chemotherapy, 2010, 65, 1771-1778.	1.3	102
411	Meropenem Dosing in Critically Ill Patients with Sepsis Receiving High-Volume Continuous Venovenous Hemofiltration. Antimicrobial Agents and Chemotherapy, 2010, 54, 2974-2978.	1.4	67
412	Antibiotic use and impact on outcome from bacteraemic critical illness: the BActeraemia Study in Intensive Care (BASIC). Journal of Antimicrobial Chemotherapy, 2010, 65, 1276-1285.	1.3	87
413	Using Population Pharmacokinetics To Determine Gentamicin Dosing during Extended Daily Diafiltration in Critically Ill Patients with Acute Kidney Injury. Antimicrobial Agents and Chemotherapy, 2010, 54, 3635-3640.	1.4	65
414	Antibiotic use and impact on outcome from bacteraemic critical illness: the BActeraemia Study in Intensive Care (BASIC). Journal of Antimicrobial Chemotherapy, 2010, 65, 2061-2061.	1.3	1

#	Article	IF	CITATIONS
415	Optimal Antibiotic Therapy in the Management of the Lung of the Critically Ill. Current Respiratory Medicine Reviews, 2010, 6, 253-263.	0.1	O
416	Respiratory Burns: A Clinical Review. Current Respiratory Medicine Reviews, 2010, 6, 285-291.	0.1	0
417	Control of an Outbreak of Carbapenem-Resistant <i>Acinetobacter baumannii</i> in Australia after Introduction of Environmental Cleaning with a Commercial Oxidizing Disinfectant. Infection Control and Hospital Epidemiology, 2010, 31, 418-420.	1.0	44
418	First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. International Journal of Antimicrobial Agents, 2010, 35, 156-163.	1.1	154
419	Therapeutic drug monitoring of $\hat{l}^2$ -lactams for critically ill patients: unwarranted or essential?. International Journal of Antimicrobial Agents, 2010, 35, 419-420.	1.1	68
420	Augmented renal clearance in the Intensive Care Unit: an illustrative case series. International Journal of Antimicrobial Agents, 2010, 35, 606-608.	1.1	81
421	Therapeutic drug monitoring of $\hat{l}^2$ -lactams in critically ill patients: proof of concept. International Journal of Antimicrobial Agents, 2010, 36, 332-339.	1.1	305
422	Antimicrobial chemotherapy and lung microdialysis: a review. International Journal of Antimicrobial Agents, 2010, 36, 491-500.	1.1	38
423	Management of Invasive Candidiasis in the Intensive Care Unit. Drugs, 2010, 70, 823-839.	4.9	21
424	Augmented Renal Clearance. Clinical Pharmacokinetics, 2010, 49, 1-16.	1.6	313
425	Augmented renal clearance in traumatic brain injury. Critical Care, 2010, 14, P521.	2.5	4
426	A novel molecular biomarker diagnostic for the early detection of sepsis. Critical Care, 2010, 14, P9.	2.5	1
427	Pharmacokinetic evaluation of piperacillin-tazobactam. Expert Opinion on Drug Metabolism and Toxicology, 2010, 6, 1017-1031.	1.5	65
428	Principles of Antibacterial Dosing in Continuous Renal Replacement Therapy. Blood Purification, 2010, 30, 195-212.	0.9	64
429	Pitfalls of using estimations of glomerular filtration rate in an intensive care population. Internal Medicine Journal, 2010, , .	0.5	5
430	Augmented Renal Clearance: Unraveling the Mystery of Elevated Antibiotic Clearance. Yearbook of Intensive Care and Emergency Medicine, 2010, , 495-506.	0.1	0
431	Augmented Renal Clearance: Unraveling the Mystery of Elevated Antibiotic Clearance., 2010,, 495-506.		3
432	A detailed feeding algorithm improves delivery of nutrition support in an intensive care unit. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2010, 12, 149-55.	0.0	2

#	Article	IF	Citations
433	A survey of antibiotic prescribing practices in Australian and New Zealand intensive care units. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2010, 12, 162-70.	0.0	8
434	The Microcirculation, Regional Blood Flow and Tissue Oxygenation: Will New Technologies Drive New Resuscitation Goals?. Anaesthesia and Intensive Care, 2009, 37, 700-702.	0.2	3
435	You Only Find what you Look for: The Importance of High Creatinine Clearance in the Critically III. Anaesthesia and Intensive Care, 2009, 37, 11-13.	0.2	22
436	Predictors and Outcome Associated with an Enterococcus Positive Isolate during Intensive Care Unit Admission. Anaesthesia and Intensive Care, 2009, 37, 976-982.	0.2	6
437	Airway Obstruction due to a Pre-vertebral Haematoma following Difficult Central Line Insertion – Implications for Ultrasound Guidance and Review of the Literature. Anaesthesia and Intensive Care, 2009, 37, 309-313.	0.2	10
438	Tissue Accumulation of Cephalothin in Burns: a Comparative Study by Microdialysis of Subcutaneous Interstitial Fluid Cephalothin Concentrations in Burn Patients and Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2009, 53, 210-215.	1.4	13
439	Unbound Cephalothin Pharmacokinetics in Adult Burn Patients Are Related to the Elapsed Time after Injury. Antimicrobial Agents and Chemotherapy, 2009, 53, 5303-5305.	1.4	8
440	Assessment of clinical risk predictive rules for invasive candidiasis in a prospective multicentre cohort of ICU patients. Intensive Care Medicine, 2009, 35, 2141-2145.	3.9	49
441	Optimising intraperitoneal gentamicin dosing in peritoneal dialysis patients with peritonitis (GIPD) study. BMC Nephrology, 2009, 10, 42.	0.8	9
442	Point of care measurement of plasma creatinine in critically ill patients with acute kidney injury. Anaesthesia, 2009, 64, 403-407.	1.8	38
443	Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. Journal of Antimicrobial Chemotherapy, 2009, 64, 142-150.	1.3	294
444	Temporal trends, risk factors and outcomes in albicans and non-albicans candidaemia: an international epidemiological study in four multidisciplinary intensive care units. International Journal of Antimicrobial Agents, 2009, 33, 554.e1-554.e7.	1.1	55
445	Clearance of intravenous 5-fluorocytosine during continuous venovenous haemodiafiltration in a patient with hepatosplenic candidiasis. International Journal of Antimicrobial Agents, 2009, 34, 383-384.	1.1	5
446	A systematic review of antibiotic dosing regimens for septic patients receiving continuous renal replacement therapy: do current studies supply sufficient data?. Journal of Antimicrobial Chemotherapy, 2009, 64, 929-937.	1.3	80
447	Management of meningitis due to antibiotic-resistant Acinetobacter species. Lancet Infectious Diseases, The, 2009, 9, 245-255.	4.6	185
448	International Study of the Prevalence and Outcomes of Infection in Intensive Care Units. JAMA - Journal of the American Medical Association, 2009, 302, 2323.	3.8	2,682
449	Pharmacokinetic issues for antibiotics in the critically ill patient. Critical Care Medicine, 2009, 37, 840-851.	0.4	755
450	Principles of antibacterial dosing in continuous renal replacement therapy. Critical Care Medicine, 2009, 37, 2268-2282.	0.4	335

#	Article	IF	CITATIONS
451	Dose matters: Dose of antibiotics in the critically ill patient depends on the dose of renal replacement therapy. Critical Care Medicine, 2009, 37, 2491-2492.	0.4	O
452	Midazolam Metabolism: Implications for Individualised Dosing?. Journal of Pharmacy Practice and Research, 2009, 39, 198-201.	0.5	3
453	A systematic review on clinical benefits of continuous administration of $\hat{l}^2$ -lactam antibiotics*. Critical Care Medicine, 2009, 37, 2071-2078.	0.4	244
454	Tissue Distribution of Beta‣actam Antibiotics: Continuous versus Bolus Dosing. Journal of Pharmacy Practice and Research, 2009, 39, 219-222.	0.5	6
455	Respiratory Complications in Burns. Clinical Pulmonary Medicine, 2009, 16, 132-138.	0.3	14
456	Piperacillin penetration into tissue of critically ill patients with sepsis—Bolus versus continuous administration?. Critical Care Medicine, 2009, 37, 926-933.	0.4	166
457	Principles of Pharmacology in the Critically Ill. , 2009, , 31-36.		0
458	A new paradigm for treating infections: "go hard and go home". Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2009, 11, 276-81.	0.0	7
459	Does severe non-infectious SIRS differ from severe sepsis?. Intensive Care Medicine, 2008, 34, 1654-1661.	3.9	66
460	A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Medicine, 2008, 34, 2226-2234.	3.9	289
461	Lessons learnt in the pharmacokinetic analysis of the effect of haemoperfusion for acute overdose with sustainedâ€release diltiazem. Anaesthesia, 2008, 63, 714-718.	1.8	14
462	A novel way to investigate the effects of plasma exchange on antibiotic levels: use of microdialysis. International Journal of Antimicrobial Agents, 2008, 31, 240-244.	1.1	13
463	Increased fluid resuscitation can lead to adverse outcomes in major-burn injured patients, but low mortality is achievable. Burns, 2008, 34, 1090-1097.	1.1	96
464	Antibiotic resistance—What's dosing got to do with it?. Critical Care Medicine, 2008, 36, 2433-2440.	0.4	299
465	Continuous infusion of $\hat{l}^2$ -lactams in the intensive care unit $\hat{a} \in \text{``Best way to hit the target?''}$ . Critical Care Medicine, 2008, 36, 1663-1664.	0.4	15
466	Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients?. Current Opinion in Critical Care, 2008, 14, 390-396.	1.6	90
467	Continuous Infusion of Time-dependent Antibiotics. Clinical Pulmonary Medicine, 2008, 15, 167-172.	0.3	1
468	Dose Adjustment and Pharmacodynamic Considerations for Antibiotics in Severe Sepsis and Septic Shock., 2008,, 97-136.		2

#	Article	IF	CITATIONS
469	Prehospital Care., 2008,, 307-319.		1
470	The entrapped central venous catheter. British Journal of Anaesthesia, 2007, 98, 89-92.	1.5	13
471	Optimizing Use of $\hat{I}^2$ -Lactam Antibiotics in the Critically III. Seminars in Respiratory and Critical Care Medicine, 2007, 28, 579-585.	0.8	17
472	Inadequate antimicrobial prophylaxis during surgery: a study of $\hat{l}^2$ -lactam levels during burn debridement. Journal of Antimicrobial Chemotherapy, 2007, 60, 166-169.	1.3	17
473	Entrapped central venous catheter. British Journal of Anaesthesia, 2007, 98, 695.	1.5	0
474	Returning to the pre-antibiotic era in the critically ill: The XDR problem*. Critical Care Medicine, 2007, 35, 1789-1791.	0.4	33
475	Resistance in the intensive care unit: Whose problem is it and how can intensivists help?*. Critical Care Medicine, 2007, 35, 299-301.	0.4	5
476	Lateral positioning of ventilated intensive care patients: A study of oxygenation, respiratory mechanics, hemodynamics, and adverse events. Heart and Lung: Journal of Acute and Critical Care, 2007, 36, 277-286.	0.8	39
477	Cefepime versus ceftazidime: considerations for empirical use in critically ill patients. International Journal of Antimicrobial Agents, 2007, 29, 117-128.	1.1	29
478	Continuous infusion of $\hat{l}^2$ -lactam antibiotics in severe infections: a review of its role. International Journal of Antimicrobial Agents, 2007, 30, 11-18.	1.1	161
479	Acute Respiratory Distress in a Bleomycin Primed Patient: A New Use for Nitric Oxide. Anaesthesia and Intensive Care, 2007, 35, 86-90.	0.2	2
480	Paralytic ileus as a complication of atropine therapy following severe organophosphate poisoning. Anaesthesia, 2007, 49, 791-793.	1.8	10
481	Autonomic dysfunction in tetanus – what lessons can be learnt with specific reference to alphaâ€2 agonists?. Anaesthesia, 2007, 62, 1066-1070.	1.8	27
482	Population pharmacokinetics and pharmacodynamics of cefpirome in critically ill patients against Gram-negative bacteria. Intensive Care Medicine, 2007, 33, 781-788.	3.9	36
483	Dose Adjustment and Pharmacokinetics of Antibiotics in Severe Sepsis and Septic Shock., 2007, , 122-146.		1
484	Prescription of Antimicrobial Agents in Patients Undergoing Continuous Renal Replacement Therapy. , 2007, , 147-158.		0
485	The implications of enterococci for the intensive care unit. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2007, 9, 69-75.	0.0	9
486	Positioning practices for ventilated intensive care patients: current practice, indications and contraindications. Australian Critical Care, 2006, 19, 122-132.	0.6	24

#	Article	IF	CITATIONS
487	Antibacterial Dosing in Intensive Care. Clinical Pharmacokinetics, 2006, 45, 755-773.	1.6	247
488	Effect of drug concentration on adsorption of levofloxacin by polyacrylonitrile haemofilters. International Journal of Antimicrobial Agents, 2006, 28, 147-150.	1.1	32
489	Manual hyperinflation causes norepinephrine release. Heart and Lung: Journal of Acute and Critical Care, 2006, 35, 262-268.	0.8	6
490	Estimate of the Number of Patients Eligible for Treatment with Drotrecogin Alfa (Activated) Based on Differing International Indications: Post-hoc Analysis of an Inception Cohort Study in Australia and New Zealand. Anaesthesia and Intensive Care, 2006, 34, 184-190.	0.2	1
491	Making the wrong choice: Consequences for patients with infections due to methicillin-resistant Staphylococcus aureus*. Critical Care Medicine, 2006, 34, 2239-2241.	0.4	5
492	Low mannose-binding lectin function is associated with sepsis in adult patients. FEMS Immunology and Medical Microbiology, 2006, 48, 274-282.	2.7	58
493	Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units. Journal of Antimicrobial Chemotherapy, 2006, 58, 987-993.	1.3	96
494	Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study. Journal of Antimicrobial Chemotherapy, 2006, 59, 285-291.	1.3	111
495	Is the end-game penetration (of the airway)?*. Critical Care Medicine, 2005, 33, 1654-1655.	0.4	33
496	Disease Risk and Mortality Prediction in Intensive Care Patients with Pneumonia. Australian and New Zealand Practice in Intensive Care (ANZPIC II). Anaesthesia and Intensive Care, 2005, 33, 101-111.	0.2	25
497	The Costs of Caring for Patients in a Tertiary Referral Australian Intensive Care Unit. Anaesthesia and Intensive Care, 2005, 33, 477-482.	0.2	49
498	Antibiotic Resistance in the Intensive Care Unit: A Primer in Bacteriology. Anaesthesia and Intensive Care, 2005, 33, 188-195.	0.2	0
499	Predictors of Physician Confidence to Diagnose Pneumonia and Determine Illness Severity in Ventilated Patients. Australian and New Zealand Practice in Intensive Care (ANZPIC II). Anaesthesia and Intensive Care, 2005, 33, 112-119.	0.2	11
500	The Spectrum of Practice in the Diagnosis and Management of Pneumonia in Patients Requiring Mechanical Ventilation. Australian and New Zealand Practice in Intensive Care (ANZPIC II). Anaesthesia and Intensive Care, 2005, 33, 87-100.	0.2	18
501	Pharmacokinetics of Colistin Methanesulfonate and Colistin in a Critically Ill Patient Receiving Continuous Venovenous Hemodiafiltration. Antimicrobial Agents and Chemotherapy, 2005, 49, 4814-4815.	1.4	122
502	The use of prophylactic fluconazole in immunocompetent high-risk surgical patients: a meta-analysis. Critical Care, 2005, 9, R710.	2.5	37
503	Fluid shifts have no influence on ciprofloxacin pharmacokinetics in intensive care patients with intra-abdominal sepsis. International Journal of Antimicrobial Agents, 2005, 26, 50-55.	1.1	51
504	Serum Procalcitonin and C-reactive Protein as Markers of Sepsis and Outcome in Patients with Neurotrauma and Subarachnoid Haemorrhage. Anaesthesia and Intensive Care, 2004, 32, 465-470.	0.2	55

#	Article	IF	CITATIONS
505	Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration. British Journal of Clinical Pharmacology, 2004, 58, 259-268.	1.1	104
506	Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Medicine, 2004, 30, 589-596.	3.9	392
507	A randomised controlled study of the efficacy of hypromellose and Lacri-Lube combination versus polyethylene/Cling wrap to prevent corneal epithelial breakdown in the semiconscious intensive care patient. Intensive Care Medicine, 2004, 30, 1122-1126.	3.9	73
508	Routine Changing of Intravenous Administration Sets Does Not Reduce Colonization or Infection in Central Venous Catheters. Infection Control and Hospital Epidemiology, 2004, 25, 650-655.	1.0	36
509	The effect of adsorption, filter material and point of dilution on antibiotic elimination by haemofiltration. International Journal of Antimicrobial Agents, 2004, 24, 468-472.	1.1	28
510	The effect of adsorption, filter material and point of dilution on antibiotic elimination by haemofiltrationAn in vitro study of levofloxacin. International Journal of Antimicrobial Agents, 2004, 24, 468-472.	1.1	44
511	Cefepime Versus Cefpirome: The Importance of Creatinine Clearance. Anesthesia and Analgesia, 2003, 97, 1149-1154.	1.1	81
512	Continuous measurement of cerebral blood flow velocity using transcranial Doppler reveals significant moment-to-moment variability of data in healthy volunteers and in patients with subarachnoid hemorrhage*. Critical Care Medicine, 2002, 30, 563-569.	0.4	33
513	Pharmacological Principles of Antibiotic Prescription in the Critically Ill. Anaesthesia and Intensive Care, 2002, 30, 134-144.	0.2	109
514	High Dependency Units: Issues to Consider in Their Planning. Anaesthesia and Intensive Care, 2002, 30, 348-354.	0.2	33
515	Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough?. Intensive Care Medicine, 2002, 28, 493-500.	3.9	38
516	Intravascular administration sets are accurate and in appropriate condition after 7 days of continuous use: an in vitro study. Journal of Advanced Nursing, 2002, 37, 330-337.	1.5	12
517	Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing. Intensive Care Medicine, 2001, 27, 363-370.	3.9	69
518	Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous haemodiafiltration. Intensive Care Medicine, 2001, 27, 665-672.	3.9	47
519	The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. Journal of Antimicrobial Chemotherapy, 2001, 47, 421-429.	1.3	171
520	Subcutaneous oxygen tensions provide similar information to ileal luminal CO2 tensions in an animal model of haemorrhagic shock. Intensive Care Medicine, 2000, 26, 592-600.	3.9	39
521	The Treatment of Tetanus with Intrathecal Baclofen. Anaesthesia and Intensive Care, 2000, 28, 438-442.	0.2	23
522	Can We Achieve Consensus on Central Venous Catheter-Related Infections?. Anaesthesia and Intensive Care, 2000, 28, 475-490.	0.2	37

#	Article	IF	CITATIONS
523	Cerebrospinal Fluid Penetration of High Doses of Intravenous Ciprofloxacin in Meningitis. Clinical Infectious Diseases, 2000, 31, 1131-1133.	2.9	51
524	Towards better ICU antibiotic dosing. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2000, 2, 282-9.	0.0	1
525	Low Plasma Cefepime Levels in Critically Ill Septic Patients: Pharmacokinetic Modeling Indicates Improved Troughs with Revised Dosing. Antimicrobial Agents and Chemotherapy, 1999, 43, 2559-2561.	1.4	115
526	Small tidal volume ventilation using a zero deadspace tracheal tube. British Journal of Anaesthesia, 1999, 82, 213-216.	1.5	6
527	Continuous infusion ceftazidime in intensive care: a randomized controlled trial. Journal of Antimicrobial Chemotherapy, 1999, 43, 309-311.	1.3	101
528	Acute respiratory distress syndrome precipitated by transjugular intrahepatic porto-systemic shunting for severe hepatic veno-occlusive disease. Is it due to pulmonary leucostasis?. Intensive Care Medicine, 1999, 25, 1332-1333.	3.9	7
529	Inter observer variability of the transcranial Doppler ultrasound technique: impact of lack of practice on the accuracy of measurement. Journal of Clinical Monitoring and Computing, 1999, 15, 179-184.	0.7	50
530	Keeping relatives informed by the internet. Lancet, The, 1999, 354, 517-518.	6.3	0
531	Vancomycin Resistance in Gram-Positive Cocciâ€"Old Bugs, New Tricks, Confusing Terminology. Anaesthesia and Intensive Care, 1999, 27, 396-399.	0.2	0
532	Critical care research and pre-emptive informed consent: a practical approach used in chris hani baragwanath ICU. Intensive Care Medicine, 1998, 24, 353-357.	3.9	10
533	Good Clinical Research Practice: What is it and is it Possible in the Intensive Care Unit?. Anaesthesia and Intensive Care, 1998, 26, 568-574.	0.2	1
534	Pharmacokinetic Profiles of High-Dose Intravenous Ciprofloxacin in Severe Sepsis. Antimicrobial Agents and Chemotherapy, 1998, 42, 2235-2239.	1.4	87
535	Intermittent bolus dosing of ceftazidime in critically ill patients. Journal of Antimicrobial Chemotherapy, 1997, 40, 269-273.	1.3	86
536	Does Intensive Care Always Have To Be Expensive Care?. Clinical Pulmonary Medicine, 1997, 4, 334-338.	0.3	0
537	CRITICAL CARE IN AFRICA. Critical Care Clinics, 1997, 13, 255-265.	1.0	16
538	Gastric intramucosal pH and blood lactate in severe sepsis. Anaesthesia, 1997, 52, 726-732.	1.8	24
539	Fungal infections in critically ill patients. BMJ: British Medical Journal, 1997, 315, 266-267.	2.4	15
540	Performance of the Pediatric Risk of Mortality Score. Critical Care Medicine, 1997, 25, 717.	0.4	0

#	Article	IF	CITATIONS
541	Pitfalls in the prediction of renal function in the intensive care unit. A review. South African Journal of Surgery, 1997, 35, 16-9.	0.1	9
542	Measurements of glomerular filtration in the intensive care unit are only a rough guide to renal function. South African Journal of Surgery, 1997, 35, 20-3.	0.1	29
543	Predictors of Mortality in Severe Malaria: A Two-Year Experience in a Non-Endemic Area. Anaesthesia and Intensive Care, 1996, 24, 217-223.	0.2	42
544	Acute stridor as a presentation of bilateral abductor vocal cord paralysis. Anaesthesia, 1996, 51, 1046-1048.	1.8	5
545	Poor discriminatory performance of the Pediatric Risk of Mortality (PRISM) score in a South African intensive care unit. Critical Care Medicine, 1996, 24, 1507-1513.	0.4	48
546	Multiple organ failure after trauma. BMJ: British Medical Journal, 1996, 313, 573-574.	2.4	11
547	A guideline for competency of the critical care nurse. American Journal of Critical Care, 1996, 5, 217-226.	0.8	19
548	Development and validation of a critical care patient classification system. American Journal of Critical Care, 1996, 5, 282-288.	0.8	3
549	Subtleties of antibiotic dosagesdo doses and intervals make a difference in the critically ill?. South African Journal of Surgery, 1996, 34, 160-2.	0.1	9
550	Accidental Intra-Arterial Adrenaline Administration. Anaesthesia and Intensive Care, 1995, 23, 488-489.	0.2	4
551	Failed Nasogastric Intubation in Undiagnosed Carcinoma of the Oesophagus. Anaesthesia and Intensive Care, 1995, 23, 370-372.	0.2	0
552	Changes in Vancomycin Pharmacokinetics in Critically III Infants. Anaesthesia and Intensive Care, 1995, 23, 678-682.	0.2	64
553	Emergency Percutaneous Balloon Mitral Valvotomy in a Patient With Septic Shock. Chest, 1995, 108, 570-572.	0.4	4
554	A Double-blind Comparison of Vecuronium Administered by the Springfusor $\hat{A}^{\otimes}$ Infusion Device to Vecuronium by Intermittent Bolus Injection in Critically Ill Adult Patients. Anaesthesia and Intensive Care, 1994, 22, 580-585.	0.2	7
555	Malignant astrocytoma of the cervico-medullary junction masquerading as Guillain-Barre syndrome Postgraduate Medical Journal, 1994, 70, 499-502.	0.9	2
556	Haemodynamic and oxygen transport response during exchange transfusion for severe falciparum malaria. Postgraduate Medical Journal, 1994, 70, 801-804.	0.9	14
557	Decreased cardiac index as an indicator of tension pneumothorax in the ventilated patient. Anaesthesia, 1994, 49, 137-141.	1.8	18
558	A comparison of arterial lines and insertion techniques in critically ill patients. Anaesthesia, 1994, 49, 968-973.	1.8	27

#	Article	IF	Citations
559	Esmolol in a case of severe tetanus. Adequate haemodynamic control achieved despite markedly elevated catecholamine levels. South African Journal of Surgery, 1994, 32, 33-5.	0.1	9
560	Acute Lung Injury at Baragwanath ICU. Chest, 1993, 103, 1832-1836.	0.4	17
561	Hydrocortisone and Tumor Necrosis Factor in Severe Community-Acquired Pneumonia. Chest, 1993, 104, 389-392.	0.4	150
562	Intensive Care Utilisation: The Baragwanath Experience. Anaesthesia and Intensive Care, 1993, 21, 396-399.	0.2	8
563	High-Dose Adrenaline in Adult In-Hospital Asystolic Cardiopulmonary Resuscitation: A Double-Blind Randomised Trial. Anaesthesia and Intensive Care, 1993, 21, 192-196.	0.2	49
564	Successful use of continuous venoâ€venous haemofiltration to treat profound fluid retention in severe peripartum cardiomyopathy. Anaesthesia, 1993, 48, 1065-1067.	1.8	11
565	Renal replacement therapy for the critically ill-precarious progress. Part II. Technical aspects and clinical application. South African Journal of Surgery, 1993, 31, 147-51.	0.1	4
566	Renal replacement therapy for the critically ill-precarious progress. Part I. Definitions and physiological aspects. South African Journal of Surgery, 1993, 31, 114-20.	0.1	4
567	Septic Shock: Does Adrenaline have a Role as a First-line Inotropic Agent?. Anaesthesia and Intensive Care, 1992, 20, 470-474.	0.2	45
568	Erythropoietin in a patient following multiple trauma. Anaesthesia, 1992, 47, 962-964.	1.8	22
569	Typhoid Fever: An Undescribed Cause of Adult Respiratory Distress Syndrome. Anaesthesia and Intensive Care, 1991, 19, 124-126.	0.2	5
570	Vasoconstrictor Effects of Adrenaline in Human Septic Shock. Anaesthesia and Intensive Care, 1991, 19, 61-65.	0.2	53
571	Comparison of disease severity scoring systems in septic shock. Critical Care Medicine, 1991, 19, 1165-1171.	0.4	33
572	The pharmacokinetics of amikacin in critically ill adult and paediatric patients: comparison of onceversus twice-daily dosing regimens. Journal of Antimicrobial Chemotherapy, 1991, 27, 81-89.	1.3	80
573	A prospective randomized study comparing once- versos twice-daily amikadn dosing in critically ill adult and paediatric patients. Journal of Antimicrobial Chemotherapy, 1991, 28, 753-764.	1.3	132
574	Acute Preload Effects of Furosemide. Chest, 1990, 98, 124-128.	0.4	27
575	Coronary embolism causing myocardial infarction. Intensive Care Medicine, 1990, 16, 215-216.	3.9	30
576	Difficulty in weaning from respiratory support in a patient with the intermediate syndrome of organophosphate poisoning. Critical Care Medicine, 1989, 17, 1075-1076.	0.4	13

#	Article	IF	CITATIONS
577	Catheter related infection. A plea for consensus with review and guidelines. Intensive Care Medicine, 1988, 14, 503-509.	3.9	39
578	Fatal infection caused by a multiply resistant type 3 pneumococcus. Journal of Clinical Microbiology, 1988, 26, 1590-1591.	1.8	11
579	Autonomic dysfunction in severe tetanus. Critical Care Medicine, 1987, 15, 987-988.	0.4	71
580	Pitfalls in the interpretation of pulmonary capillary wedge pressure. South African Medical Journal, 1985, 67, 174-7.	0.2	8
581	Vitamin B12 levels in the prolonged use of sodium nitroprusside. Critical Care Medicine, 1984, 12, 161-163.	0.4	6
582	Intravenous calcium chloride as an antidote to verapamil-induced hypotension. Intensive Care Medicine, 1982, 8, 55-57.	3.9	37
583	Antibiotic Dosing in Critically Ill Patients. , 0, , 128-128.		O
584	Use and Abuse of Antibiotics. , 0, , 128-136.		0
585	Plasma and Interstitial Fluid Pharmacokinetics of Prophylactic Cefazolin in Elective Bariatric Surgery Patients. Antimicrobial Agents and Chemotherapy, 0, , .	1.4	4